A Systematic Review on Predisposition to Lymphoid (B and T cell) Neoplasias in Patients With Primary Immunodeficiencies and Immune Dysregulatory Disorders (Inborn Errors of Immunity)

Irbaz Bin Riaz¹, Warda Faridi², Mrinal M. Patnaik¹ and Roshini S. Abraham³∗

¹ Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, United States, ² Department of Hematology, University of Arizona, Tucson, AZ, United States, ³ Department of Pathology and Laboratory Medicine, Nationwide Children’s Hospital, Columbus, OH, United States

Primary immunodeficiencies and immune dysregulatory disorders (PIDDs; now referred to as inborn errors in immunity) are rare disorders with a prevalence of 41. 4 or 50.5 per 100,000 persons (1). The incidence of malignancy in PIDD patients is the second-highest cause of death in children as well as adults, after infection, and is higher in certain PIDDs compared to others. We performed a systematic review of the literature to identify reports of B cell and T cell neoplasias in PIDDs and clustered them based on their classification in the IUIS schema. As would be expected, higher susceptibility to malignancies are typically reported in patients with Common Variable Immunodeficiency (CVID), combined immunodeficiencies affecting cellular immunity, in particular, DNA repair defects, or in the context of impaired immune regulatory control. There is not much evidence of increased risk for cancer in patients with innate immune defects, indicating that not all types of infection or genetic susceptibility predispose equally to cancer risk. Viral infections, in particular EBV, HHV and HPV, have been shown to increase susceptibility to developing cancer, but also patients with defects in immune regulation, such as Autoimmune Lymphoproliferative Syndrome (ALPS), activated p110delta syndrome (APDS type 1) and IL-10 receptor deficiency among others have a higher incidence of neoplastic disease, particularly lymphomas. In fact, lymphomas account for two-thirds of all malignancies reported in PIDD patients (2), with either a combined immunodeficiency or DNA repair defect predominating as the underlying immune defect in one registry, or antibody deficiencies in another (3). The vast majority of lymphomas reported in the context of PIDDs are B cell lymphomas, though T cell lymphomas have been reported in a few studies, and tend to largely be associated with chromosomal breakage disorders (4) or...
INTRODUCTION

Monogenic and other genetic defects of the immune system, now collectively grouped as primary immunodeficiencies and immune dysregulatory disorders (PIDDs) affect various components of the immune system with susceptibility to infections, but also to autoimmunity, malignancies, and other manifestations of immune dysregulation (7–9). The number of genetically defined PIDDs is increasing with the current tally at well over 300 genes (10), and several of these are associated with an increased predisposition to developing neoplastic disease (11). Early studies have suggested a variable prevalence of malignancies in PIDDs with approximately 25% affected with cancer at the higher end of the spectrum (7). A recent large study spanning 12 years for patients enrolled in a national registry (USIDNET) revealed an age-adjusted cancer risk, as well as a gender-associated cancer risk with male patients predominating in this cohort (12). The largest proportion of risk was conferred by susceptibility to hematopoietic malignancies rather than solid tumors, in particular lymphoma. Herein, we describe a targeted literature review on the associations of B and T cell lymphomas with PIDDs, particularly with regard to specific immune defects. We will also reflect on current state of knowledge as regards to pathogenesis and management of lymphoid neoplasias in PIDDs.

METHODS AND RESULTS

In these sections, we describe the strategy to identify relevant citations gathered for this review and a summary of the results. A comprehensive search of the MEDLINE database was initially conducted from its inception to October 17th, 2018. The search was updated on February 1st, 2019. Controlled vocabulary supplemented with keywords (which included lymphoma) was used to search for individual primary immunodeficiencies as per the IUIS 2017 classification. Search results and study selection are outlined in Figure 1. Number of cases and type (B, T or unspecified) are shown in Figure 2. The cases of B cell lymphomas, T cell lymphomas and unspecified lymphomas in PIDDs are summarized in Tables 1–3 respectively.

B CELL LYMPHOMAS IN PIDDs

A thorough search of the literature using Medline database (via PubMed; Figure 1) identified 86 studies reporting B cell lymphoma in PIDD patients. Table 1 gives details of the 456 patients identified from literature plus two unpublished cases from our center (Mayo Clinic, Rochester). The types of B cell lymphoma were unspecified non-Hodgkin Lymphoma (NHL) (37%, n = 171), diffuse large B cell lymphoma (DLBCL) (15%, n = 68), Hodgkin lymphoma (HL) (13%, n = 59), marginal zone lymphoma (MZL) including extranodal and intranodal MZL (5%, n = 23), Burkitt lymphoma (BL) (4%, n = 17) and diffuse histiocytic lymphoma (DHL) (0.4%, n = 2). Unlike T cell lymphomas where most of cases were reported in males, gender distribution was similar in males (29%, n = 130) and females (34%, n = 157), it was not specified (NS) in 37% (n = 169). The age of onset/diagnosis of lymphoma ranged from 7 months to 76 years (median age: 12 years). EBV association was seen in 25% (n = 113) of the patients. The majority of patients received combination chemotherapy as a standard treatment. While allogeneic hematopoietic cell transplantation (HCT) was not performed in many of these cases, it appeared to be successful in achieving a complete response (CR) in some cases. Serious infectious complications and death were frequently associated with chemotherapy treatment. Individual groups of PIDDs are examined in further detail based on the IUIS classification.

IUIS: Immunodeficiencies Affecting Cellular and Humoral Immunity

There were 12 studies which included 13 patients with B cell lymphoma. Adenosine deaminase 1 (ADA1) deficiency was most common immunodeficiency disease in this category (19–24). The other 7 cases include patients with an underlying diagnosis of Coronin 1A and DNA Ligase IV deficiencies, Artemis-SCID, RAG1, and ZAP70 defects (13–18, 24, 107). Of these 13 cases, 69% (n = 9) patients were females, 15% (n = 2) were males and 15% (n = 2) were NS. DLBCL (62%, n = 8) was the most common type of B cell neoplasm identified followed by unspecified B cell lymphoma (15%, n = 2). The median age at presentation was 1.5 years (range 0.9–14 years) and all patients were EBV-positive. The most common clinical presentation was lymphadenopathy and high fevers. The underlying etiology for the development of lymphoma appeared to be DNA repair defects and EBV association. All patients were treated with some form of combination chemotherapy, most commonly, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP). Of these 7 cases, only 2 patients survived and were in complete remission at follow-up. One patient who developed DLBCL in the setting of RAG1 deficiency had a partial response with rituximab, which was consolidated by HCT from an HLA-matched unrelated donor. Though there is no long-term follow-up data in this report, the patient had no evidence of disease at 3 years follow-up (16).
Adenosine Deaminase 1 (ADA1) Deficiency
B cell lymphoma with ADA1 deficiency was seen in six patients, three of whom had EBV association (19–24). Only one patient was reported to be in complete remission 20 months after diagnosis, others died despite treatment.

IUIS: Combined Immunodeficiency Disorders With Associated or Syndromic Features
In this category, 27 studies plus two unpublished cases reported B cell lymphomas in 191 patients with combined immunodeficiency disorders with associated or syndromic features. Of these, 41% (n = 78) cases were associated with EBV infection, and the lymphoma was diagnosed at median age of 10 years. In this cohort there appeared to be a preponderance of males at 38% (n = 73) with females accounting for 32% (n = 62) and 30% (n = 56). Some of the more common genetic disorders are discussed further.

Ataxia Telangiectasia (AT)
Over one-third (35%, n = 67) of the reported cases of lymphoma in this IUIS category were in the setting of ataxia telangiectasia, which is an autosomal recessive disorder with immunodeficiency, DNA repair defects and neurological complications(3, 25–28, 38, 41). Lymphomas were diagnosed across all ages of patients typically manifesting before 10 years of age with the oldest cases being reported at 16 years of age. Original reports reported the histology as DLBCL or unspecified NHL in 75% (n = 50), HL in 21% (n = 14), BL in 3% (n = 2), and MZL in 1% (n = 1) of cases. The most common presenting symptoms included extensive lymphadenopathy. A French study reported a crude incidence of cancer of 24.7% in AT with B cell lymphoid malignancies representing the majority of cases. The pathological diagnosis of lymphoma in these patients can be challenging, and it is relevant to note that three of the four T-cell NHLs, based on pathology, were reclassified as B-cell NHLs after centralized pathology review. The median overall survival (OS) decreased from 24 to 15 years in AT patients with malignant disease. In fact, the common causes of mortality in this group were either cancer (47%) or infectious complications (34%). There was a trend toward increased survival if there was an excellent response to chemotherapy. Though the overall prognosis in AT remains relatively poor, a subset of these of patients might benefit from treatment of the malignancy with an improved survival (25).

Wiskott-Aldrich Syndrome (WAS)
There were 6 studies identified, which reported B cell lymphoma in 6 patients (median age 14 years) with WAS, which is an
TABLE 1 | Summary of B cell lymphomas in PIDDs.

| PID | References | N | Proposed mechanism | Cancer | Specific mutations | Age/sex | Manifestation/course | Treatment | Outcome |
|-----|------------|---|--------------------|--------|--------------------|---------|----------------------|-----------|---------|
| **IMMUNODEFICIENCIES AFFECTING CELLULAR AND HUMORAL IMMUNITY** | | | | | | | | | |
| Coronin 1a deficiency* | (13) | 2 | EBN associated | Pt1: DLBCL | Coronin-1a mutation: V134M/V134M | 1/M | Left orbit mass | Chemotherapy | FU at 11.5 y = CR |
| | | | | Pt2: DLBCL | Coronin-1a mutation: V134M/V134M | 0.6/F | Gero-cothoracicobdominal LN and cerebral lesion | Chemotherapy | Died during induction therapy at 8.5m of age |
| DNA Ligase IV mutation* | (14) | 1 | EBN associated | DLBCL | LigIV gene: M249V substitution and a 5 nucleotide del from 1,270–1,274 | 14/F | Progressive gingival swelling and high fever | Vincristine, cyclophosphamide, and prednisolone | Died of respiratory aspergillosis |
| Artemis-SCID* | (15) | 1 | DNA repair defect | BCL | Hypomorphic mutations of the Artemis gene | 5/F | Liver, lung, LN, skeletal muscle involvement | Rituximab | Died of lymphoma |
| RAG 1 mutation* | (16) | 1 | NR | DLBCL | RAG1 gene: Allele 1 R314W Allele 2 R507W/R737H | 2/F | Tumor of right tonsil | Rituximab, HSCT | CR |
| DNA Ligase IV mutation* | (17) | 1 | DNA repair defect | EBN associated | Compound heterozygous for a null allele and a hypomorphic mutation in DNA LigIV | 2/F | High fever, cervical LN, hepatomegaly, necrotizing mucositis | Chemotherapy | Pt. died of aspergillosis |
| ZAP70 deficiency* | (18) | 1 | EBN associated | DLBCL | ZAP70 Gene: c.836_837 delAT | 1/F | Generalized lymphadenopathy | Vincristine, cyclophosphamide, methylprednisolone | Died of DIC, multiorgan failure |
| ADA deficiency* | (19) | 1 | EBN associated | NR | NR | NR | NR | NR | Died 1 week later |
| | (20) | 1 | EBN associated (suspected) | Immunoblastic plasmacytoid | NR | NR | NR | NR | Died at 4 y |
| ADA deficiency | (21) | 1 | NS | DLBCL | A83D; Exon 5 splice donor site c.573 + 1G > A | 10/M | 6-week history of headache, eye deviation, and weakness. | COP + APO + 6-IMP; MTX | Died after 5 m |
| ADA deficiency | (22) | 1 | Immune dysregulation | BL | Homozygous Q2X | 14/F | Right hip pain and limping | Chemotherapy | CR 20m later |
| ADA deficiency | (23) | 1 | Immune dysregulation | DLBCL | Homozygous W272X (c.815G > A) | 3/F | Respiratory complaints and symptoms | BFM 2004 protocol | Died of septic shock and intracranial hemorrhage after starting treatment |
| ADA deficiency* | (24) | 1 | EBN associated | Plasmablastic | Homozygous 462delG | 18/F | Persistent fever, multiple lymphadenopathies and bilateral periportal edema | Rituximab; APO; and cyclophosphamide + dexamethasone | Patient died of a hemorrhagic alveolitis, 12 days after starting chemotherapy |
| **COMBINED IMMUNODEFICIENCIES WITH ASSOCIATED OR SYNDROMIC FEATURES** | | | | | | | | | |
| Ataxia Telangiectasia* | (25) | 12 | NS | HL | NS | 10/8M, 4F | NR | NS | 10 pts died |
| | 38 | NS | NHL | NS | 9/22M, 16F | NR | NS | 28 pts died |
| Ataxia Telangiectasia* | (26) | 1 | DNA repair defect | MZL | NS | 16/M | Chronic lymphadenitis, LN at left jaw, Cervical, colic, para-aortic LN, | Rituximab | CR |
| | (27) | 1 | DNA repair defect | HL | NR | 14/M | Cervical, axillary and mediastinal LN | COPP | CR |
| Ataxia Telangiectasia* | (28) | 1 | EBN associated | NHL | ATM gene (exon 39 and c.6905GAA) | 13/M | Waldenström's ring, intrapulmonary, abd., tonsillar, cervical LN | Rituximab, doxorubicin, dexamethasone, cytarabine, cyclophosphamide, etoposide, vincristine, HSCT | No recurrence on 3 y FU |
| Wiskott Aldrich* | (29) | 1 | EBN associated | DBCL | NR | 14/M | Cervical adenitis, neurological symptoms | Rituximab | Died |
| Wiskott Aaldrich* | (30) | 1 | NS | BL | WASP gene missense mutation (105 C > T) in exon 1 | 12/M | Recurrent colicky abd. pain and bloody stool | Rituximab, CHOP | CR |

(Continued)
| PID          | References | N  | Proposed mechanism | Cancer          | Specific mutations | Age/sex | Manifestation/course                          | Treatment                                           | Outcome                        |
|-------------|------------|----|--------------------|-----------------|-------------------|---------|-----------------------------------------------|-----------------------------------------------------|--------------------------------|
| Wiskott Aldrich* | (31)      | 1  | EBV associated     | DLBCL           | NS                | 15/M   | Progressive respiratory distress, night sweats | Cyclophosphamide, prednisone, radiotherapy, laser surgery | Died of lung infection     |
| Wiskott Aldrich* | (32)      | 1  | EBV associated     | HL              | NS                | 1      | Pulmonary hilar LN                            | ABVD                                               | CR for more than 4 y         |
| Wiskott Aldrich* | (33)      | 1  | EBV associated     | NHL             | NR                | 20/M   | Lymphadenopathy, CNS, gastric wall, pulmonary lesions | Acyclovid, adenosine arabinoside                  | Died of sepsis               |
| Wiskott Aldrich* | (34)      | 1  | EBV associated     | IL              | NS                | 13/M   | Rectosigmoid tumor                             | Chemotherapy, excision, L-asparaginase therapy          | Died of colon perforation   |
| DiGeorge Syndrome* | (35)     | 1  | EBV associated     | INHL            | NS                | 10/m/F | Hemiparesis due to cerebral mass, mediastinal LN | Untreated                                          | Died                          |
| Cartilage hair dysplasia* | unpublished | 1  | EBV associated    | DLBCL           | RMRP gene         | 51/M   | Incidental lung nodule                         | R-CHOP                                              | CR                            |
| Cartilage hair dysplasia* | unpublished | 1  | EBV associated    | MCL             | RMRP gene         | 47/M   | Fever, night sweats, lymphadenopathy            | Rituximab Under treatment with Rituximab for recurrence | Under treatment with Rituximab for recurrence |
| Cartilage hair dysplasia | (36)      | 10 | NS                |                 |                  |        |                                               |                                                     |                               |
| Pt1: HL      |            |    |                   | 70A > G/70A > G | 20/M             | NR     |                                               |                                                     | Died in 1 m                   |
| Pt2: NHL     |            |    |                   | 70A > G/262G > T| 40/M             | NR     |                                               |                                                     | Died same m                   |
| Pt3: NHL     |            |    |                   | dupTACTCTGTGTA at 13/70A > G | 45/F | NR |                                               |                                                     | Died in 3 m                   |
| Pt4: NHL     |            |    |                   | 70A > G/70A > G | 46/F             | NR     |                                               |                                                     | Died in 6 m                   |
| Pt5: NHL     |            |    |                   | Not tested      | 22/F             | NR     |                                               |                                                     | Died in 2 m                   |
| Pt6: NHL     |            |    |                   | 70A > G/70A > G | 6/F              | NR     |                                               |                                                     | Died in 9 m                   |
| Pt7: NHL     |            |    |                   | Not tested      | 21/M             | NR     |                                               |                                                     | Died in 1 m                   |
| Pt8: NHL     |            |    |                   | Not tested      | 26/M             | NR     |                                               |                                                     | Died in 1 m                   |
| Pt9: NHL     |            |    |                   | 70A > G/70A > G | 32/M             | NR     |                                               |                                                     | Alive 4.5 y                  |
| Pt10: NHL    |            |    |                   | 70A > G/70A > G| 33/F             | NR     |                                               |                                                     | Alive 4.5 y                  |
| NBS          | (37)       | 8  |                   |                 |                  |        |                                               |                                                     |                               |
| Pt1: DLBCL   |            |    | Homozygous 657delG| 10/M            | DLBCL at 10, 18, 23 and 26y | 1st event unknown, 2nd LMB-89-9, 3rd R-CHOP, 4th DHAP | Alive, CR at 27 y                                |                               |
| Pt2: DLBCL   |            |    | Homozygous 657delG| 14/F            | DLBCL at 14, 20y | 1st event unknown, 2nd LMB-89 without MTX | Died of liver failure after CYM protocol at 20 y |                               |
| Pt3: DLBCL   |            |    | Homozygous 657delG| 4/F             | NR              | LMB-89, without CTX, followed by individualized chemotherapy | Died of disease after second individual protocol at 5 y |                               |
| Pt4: DLBCL   |            |    | Homozygous 657delG| 6/F             | NR              | LMB-89, without CTX, followed by individualized chemotherapy | Died of disease at 7 y                            |                               |
| Pt5: DLBCL   |            |    | Homozygous 657delG| 11/F            | NR              | LMB-89, without CTX, followed by individualized chemotherapy | Died of disease at 12 y                           |                               |
| Pt6: DLBCL   |            |    | Homozygous 657delG| 23/M            | Switch from DLBCL to AILT at 20y | LMB-89; for AILT: BFM-90 followed by individualized chemotherapy | Died of disease after individual protocol at 27 y |                               |
| Pt7: BL      |            |    | Homozygous 657delG| 9/M             | Burkitt like lymphoma at 9, followed by DLBCL at 10 | 1st LMB-89, 2nd LMB-89 followed by individualized chemotherapy and splenectomy | Alive at 16 y                              |                               |
| PID       | References | N  | Proposed mechanism | Cancer | Specific mutations | Age/sex | Manifestation/course | Treatment | Outcome                        |
|-----------|------------|----|--------------------|--------|--------------------|---------|----------------------|-----------|--------------------------------|
| NBS       | (38)       | 11 | NS                 |        |                    |         |                      |           |                                |
| Pt1: BL   |            |    |                    |        | Homozygous 657del5  | 5/F     | NR                   | LMB-89    | PR, alive at 12               |
| Pt2: BL   |            |    |                    |        | 657del5            | 9/M     | NR                   | NHL-BFM90 | CR 11 y after diagnosis       |
| Pt3: BL   |            |    |                    |        |                    | 15/F    | B-NHL at 31 y, third malignancy, Bi-lineage leukemia at 34 y | NHL-BFM90 modified | Died at 3.4 y from 3rd malignancy |
| Pt4: IL   |            |    |                    |        |                    | 4/M     | 2nd BL at 10 y       | NHL-BFM90 | CR at 11 y                     |
| Pt5: FL   |            |    |                    |        |                    | 10/F    | NR                   | NHL-BFM90 switched to CHOP because of progressive disease | CR at 11 y | Died 4.5 y after diagnosis    |
| Pt6: BL   |            |    |                    |        |                    | 7/F     | 2nd DLBCL, third malignancy, B-NHL (DLBCL) | NHL-BFM95 | Current under treatment (NHL-BFM modified) |
| Pt7: DLBCL|            |    |                    |        |                    | 5/M     | NR                   | NHL-BFM95 | CR 6 y after diagnosis        |
| Pt8: DLBCL|            |    |                    |        |                    | 5/F     | 2nd malignancy: ALC-L T 3.5 y after diagnosis | NHL-BFM95 modified | Death of lung infection 8 y after diagnosis |
| Pt9: NHL  |            |    |                    |        |                    | 15/M    | NR                   | NHL-BFM95 + Rituximab | CR 4 y after diagnosis |
| Pt10: DLBCL|           |    |                    |        |                    | 10/F    | NR                   | NHL-BFM95 modified | Death of lung infection 11 y after diagnosis |
| Pt11: ALC-L |          |    |                    |        |                    | 16/M    | NR                   | B-NHL-BFM90 modified | Chronic lung disease, death of pulmonary infection 11.9 y after diagnosis |
| Pt12: BL  |            |    |                    |        |                    | 7/M     | NR                   | B-NHL BFM90 modified + Rituximab-Window | CR 2.7 y after diagnosis |
| Pt3: DLBCL|            |    |                    |        |                    | 6/M     | NR                   | B-NHL BFM90 modified | CR 3.8 y after diagnosis |
| Pt4: DLBCL|            |    |                    |        |                    | 9/F     | NR                   | NHL-BFM90 modified | Death of early relapse 1 y after diagnosis |
| Pt5: DLBCL|            |    |                    |        |                    | 5/M     | 2nd malignancy: DLBCL 10 y after diagnosis | NHL-BFM95 modified | CR 2.7 y after diagnosis |
| Pt6: DLBCL|            |    |                    |        |                    | 11/M    | 2nd malignancy: DLBCL 3 y after diagnosis | NHL-BFM95 modified | Death with pulmonary failure  |
| Pt7: DLBCL|            |    |                    |        |                    | 7/F     | NR                   | NHL-BFM95 modified | CR 9.6 y after diagnosis |
| Pt8: DLBCL|            |    |                    |        |                    | 10/F    | NR                   | NHL-BFM95 modified | CR 9.6 y after diagnosis |
| Pt9: DLBCL|            |    |                    |        |                    | 9/F     | NR                   | NHL-BFM95 modified | CR 7 y after diagnosis       |
| Pt10: DLBCL|           |    |                    |        |                    | 9/F     | NR                   | NHL-BFM95 modified | CR 7 y after diagnosis       |
| Pt11: HL  |            |    |                    |        |                    | 12/M    | NR                   | No chemotherapy | Death of progressive disease 1 y after diagnosis |
| Ataxia Telangiectasia |       | 11 | NS                 |        |                    |         |                      |           |                                |
| Pt1: BL   |            |    |                    |        |                    | 16/M    | NR                   | B-NHL BFM90 modified + Rituximab-Window | CR 2.7 y after diagnosis |
| Pt2: BL   |            |    |                    |        |                    | 7/M     | NR                   | B-NHL BFM90 modified + Rituximab-Window | CR 2.7 y after diagnosis |
| Pt3: BL   |            |    |                    |        |                    | 6/M     | NR                   | B-NHL BFM90 modified + Rituximab-Window | CR 2.7 y after diagnosis |
| Pt4: BL   |            |    |                    |        |                    | 9/F     | NR                   | NHL-BFM90 modified | Death of early relapse 1 y after diagnosis |
| Pt5: BL   |            |    |                    |        |                    | 5/M     | 2nd malignancy: DLBCL 10 y after diagnosis | NHL-BFM95 modified | CR 2.7 y after diagnosis |
| Pt6: BL   |            |    |                    |        |                    | 11/M    | 2nd malignancy: DLBCL 3 y after diagnosis | NHL-BFM95 modified | Death with pulmonary failure  |
| Pt7: BL   |            |    |                    |        |                    | 7/F     | NR                   | NHL-BFM95 modified | CR 9.6 y after diagnosis |
| Pt8: BL   |            |    |                    |        |                    | 10/F    | NR                   | NHL-BFM95 modified | CR 9.6 y after diagnosis |
| Pt9: BL   |            |    |                    |        |                    | 9/F     | NR                   | NHL-BFM95 modified | CR 7 y after diagnosis       |
| Pt10: BL  |            |    |                    |        |                    | 9/F     | NR                   | NHL-BFM95 modified | CR 7 y after diagnosis       |
| Pt11: BL  |            |    |                    |        |                    | 12/M    | NR                   | No chemotherapy | Death of progressive disease 1 y after diagnosis |

(Continued)
| PID       | References | N   | Proposed mechanism                           | Cancer       | Specific mutations | Age/sex | Manifestation/course                                                                 | Treatment                  | Outcome        |
|-----------|------------|-----|---------------------------------------------|--------------|--------------------|---------|---------------------------------------------------------------------------------------|----------------------------|----------------|
| NBS*      | (40)       | 11  | Two cases possibly EBV associated           | DLBCL        | Homozygous 657del5 | 17/F    | Bilateral cervical LN, malaise, headache, epistaxis, symptoms of URI, fever, night sweats, and loss of weight, followed by the development of protruding tissue mass in the epigastrium | Modified CHOP + Rituximab | Alive at 15 y |
| NBS       | (41)       | 4   | NS                                          | DLBCL        | Homozygous 657del5 | 15/F    | NHL-BFM                                                                                 | CR, LFU = 6 y              |                |
| NBS*      | (42)       | 1   | Defective DNA repair                         | DLBCL        | Homozygous 657del5 | 5/F     | Fever lasting for 2 m and mediastinal adenopathy                                         | COPP/ABV                   | CR, 2 y in CR on LFU |
| NBS*      | (43)       | 12/57 | EBV associated                               | HL           | Homozygous 657del5 | 5/F     |                                                                                         |                             | 15 out of total 22 patients died, but 7 were clinically stable after early diagnosis and successful treatment |
| NBS       | (44)       | 2/57 | Chronic antigenic stimulation                | NHL          | NR                 | NR      |                                                                                         |                             |                |
| NBS       | (45)       | 30/149 | NS                                          | NHL          | NR                 | NR      |                                                                                         |                             | 44% of all patients in CR, 54% dead due to disease progression |
| Dyskeratosis Congenita | (46) | 1   | Genetic instability                          | HL           | NR                 | NR      |                                                                                         | Radiation-chemotherapy      | Died after 25 y (gastric adenocarcinoma) |
| Ataxia Telangiectasia | (47) | 1/10 | NS                                          | 1 NHL        | NR                 | NR      |                                                                                         |                             |                |
TABLE 1 | Continued

| PID | References | N | Proposed mechanism | Cancer | Specific mutations | Age/sex | Manifestation/course | Treatment | Outcome |
|-----|------------|---|--------------------|--------|--------------------|---------|----------------------|-----------|---------|
| Ataxia Telangiectasia | (41) | 2 | NS | Pt1: DLBCL | NR | 9/F | NHL-BFM | Relapse after 10 m, died after 1 y of diagnosis |
| | | | | Pt2: DLBCL, ALCL (3) | NR | 12/M | NHL-BFM dosages reduced | BM/T (thymoplasid), CR, BM/T-related death |
| PNP deficiency | (41) | 1 | NS | P2: DLBCL | NR | 2/F | NHL-BFM | Died due to aplasia following chemotherapy |
| Schimke Immuno-Osseous dysplasia | (47) | 1 | NR | NHL | SMARCAL1 missense mutation (R961H) | 8/M | Colicky abdominal pain and vomiting. Palpation of the abdomen revealed a hard mass in right upper abdomen. Intussusception secondary to NHL | Vincristine, cyclophosphamide, Adriamycin and intrathecal methotrexate using half of their usual doses | CR, LFU +1 y |
| | | | | NHL | SMARCAL1 mutation | NR | NR | NR | NR |
| | | 3/1 | NS | NHL | Homozygous mutation of the SMARCAL1 gene (1146–1147delAA & IVS6 þ 2delGT) | 5/M | Fever, mild cough | Chemo therapy | Died 1 m later due to multorgan failure |
| Schimke Immuno-Osseous dysplasia* | (49) | 1 | EBV associated | BCL | NHL | 5/M | Suspected purulent bilateral conjunctivitis: Unresponsive On microscopy: salmon-colored, nodular lesions | Topical IFN-α (α); 3 times a day; 300,000 U/drop. |Resolved. No lesions at 1 y FU |
| CHARGE association with Hyper-IgM | (50) | 1 | Chronic antigenic stimulation | MZL | NR | 5/F | | |
| Severe Ig deficiency | (41) | 1 | NS | DLBCL | NR | 14/F | VBL for palliation only | Died after 3 m |
| IgG1, −3 and −4 deficiency | (41) | 1 | NS | BL | NR | 6/F | NHL-BFM | CR, LFU +6 y |
| Selective IgA deficiency | (41) | 1 | NS | Burkitt-like | NR | 2/M | NHL-BFM | CR, LFU +0.5 y |
| IgG4 and IgM deficiency | (41) | 1 | NS | BL | NR | 5/F | NHL-BFM | CR, LFU +4.5 y |
| IgA, IgG2, and −4 deficiency | (41) | 1 | NS | BL | NR | 11/M | NHL-BFM | Reached CR, died of sepsis after second therapy course |
| APDS | (51) | 2/8 | NS | P1: DLBCL, GOF mutation in the PIK3CD gene: E1021K (c.3061G > A) | NR | 8/M | 2nd DLBCL at 19 y | Died after large bowel perforation and bleeding 12 days after the third course of chemotherapy |
| | | | | P2: HL | Heterozygous GOF mutation in the PIK3CD gene: E1021K | 11/M | Caracil LN enlargement | CR, alive FU of more than 10 y |
| | | 6/53 | NS | P2: HL | Heterozygous GOF mutation in the PIK3CD gene: E1021K | 1.5–27/NR | NR | 3 died |
| APDS | (52) | 1/17 | NS | MZL | E1021K mutation | 38/M | NR | NR |
| | | 1/386 | NS | NHL | NR | 47/M | Abdominal pain, numbness, and weakness in legs. | FU 3.5 y; OR |
| CVID | (55) | 1 | NS | DHL | NR | 16/F | Cough, wheezing | Prednisolone | Alive |
| | | 1 | NS | EZML | 44/F | Chlorambucil and prednisone | Recurrence after 6 m | |
| | (56) | 1 | NS | EZML | 16/F | Cough, wheezing | Prednisolone | Alive |
| | (57) | 1 | NS | EZML | 44/F | Chlorambucil and prednisone | Recurrence after 6 m | |

(Continued)
TABLE 1 | Continued

| PID | References | N | Proposed mechanism | Cancer | Specific mutations | Age/sex | Manifestation/course | Treatment | Outcome |
|-----|------------|---|--------------------|--------|--------------------|---------|----------------------|-----------|---------|
| CVID | (58) | 54 | EBV possibly | BCL | NR | NR | NR | NR | NR |
| CVID* | (59) | 3/220 | EBV associated | BCL | NR | NR | NR | NR | NR |
| CVID | (60) | 7 | NS | BCL | NR | 46**/F | NR | NR | NR |
| CVID* | (61) | 1 | EBV or ITK mutation | HL | NR | 25/F | NR | Rituximab and brentuximab vedotin. | CR |
| CVID | (62) | 3 | NS | BCL | NR | 2/M | Generalized LN | NR | Died at 23y |
| CVID | (63) | 22/248 | NS | NHL | NR | 13/F | Chemotherapy (CHOP) | Died, age 13 |
| CVID | (64) | 5/5 | NS | EZMZL | NR | 52/F | Radiation | Died, age 66 |
| CVID | (65) | 5/5 | NS | EZMZL | NR | 52/F | Surgery | Died, age 66 |
| CVID | (66) | 5/5 | NS | EZMZL | NR | 52/F | Surgery, chemotherapy | Died, age 66 |
| CVID | (67) | 5/5 | NS | EZMZL | NR | 52/F | Surgery | Died, age 66 |
| CVID | (68) | 5/5 | NS | EZMZL | NR | 52/F | Surgery | Died, age 66 |
| CVID | (69) | 5/5 | NS | EZMZL | NR | 52/F | Surgery | Died, age 66 |
| CVID | (70) | 5/5 | NS | EZMZL | NR | 52/F | Surgery | Died, age 66 |

(Continued)
TABLE 1 | Continued

| PID         | References | N   | Proposed mechanism                                      | Cancer     | Specific mutations | Age/sex | Manifestation/course | Treatment               | Outcome               |
|-------------|------------|-----|--------------------------------------------------------|------------|--------------------|---------|----------------------|-------------------------|-----------------------|
| CVID        | (65, 66)   | 9/117 | Unknown                                                | P1: DLBCL  | NR                 | 12/F    | Liver, Spleen          | CHOP                    | Died at 13 y           |
|             |            |      | P2: DMSL                                              | NR         |                    | 54/F    | Right inguinal Node   | CHOP                    | Died at 69 due to other |
|             |            |      | P3: DMSL                                              | NR         |                    | 50/F    | Pelvis,                | CHOP                    | Died at 56 y           |
|             |            |      | P4: DLBCL                                             | NR         |                    | 48/F    | Proximal jejunum       | Surgery                 | Alive, 8 y later        |
|             |            |      | P5: Follicular                                        | NR         |                    | 54/F    | Parotid, 1 y later FL in axilla | Surgery for both | Alive, after 3 y        |
|             |            |      | P6: diffuse small cleaved cell                        | NR         |                    | 56/F    | Pelvic nodes           | M-BACOD, CHOP, RT, CP   | Alive                 |
|             |            |      | P7: DLBCL                                             | NR         |                    | 57/F    | Supracervical area, abdomen | C-MOPP                 | Died at age 68         |
|             |            |      | P8: DLBCL                                             | NR         |                    | 65/F    | Lymph nodes, lungs     | C-MOPP                  | Died at age 72         |
|             |            |      | P9: DLBCL                                             | NR         |                    | 70/F    | Cervical lymph nodes   | Alpha-interferon        | Alive                 |
|             | (54)       | 5/176 | NS                                                    | P1: NHL    | NR                 | 52/F    | NR                    | NR                      | NR                    |
|             |            |      | P2: NHL                                              | NR         |                    | 59/F    | NR                    | NR                      | NR                    |
|             |            |      | P3: NHL                                              | NR         |                    | 76/F    | NR                    | NR                      | NR                    |
|             |            |      | P4: HL                                               | NR         |                    | 49/F    | NR                    | NR                      | NR                    |
| CVID        | (67)       | 1    | Defective antitumor immunosurveillance                | DHL        | NR                 | 44/F    | Abdom. pain, slight diarrhea, weight loss, Reversible mass in right abdomen | Resection and irradiation | 4-y F/U: OR            |
| CVID        | (68)       | 1    | Chronic antigenic stimulation                         | IL         | NR                 | 75/M    | Weight loss, numbness and tingling in extremities | Surgical resection | Death post-op due to septicemia |
| CVID        | (69)       | 1    | Defective antitumor immunosurveillance                | MZL        | NR                 | 39/M    | Perianal pain, severe diabetes, weight loss | NR                      | NR                    |
| CVID        | (70)       | 42/24| NS                                                    | NHL        | NR                 | NR      | NR                    | Chemotherapy + Rituximab + transplant | NR                    |
| CVID        | (71)       | 52/47| NS                                                    | Jejunal, 1 histiocytic, 1 HL, 2 BCL, 1 EMZL, 1 NHL, 1 MM | NR     | NR                    | NR                      | 4 died, HL responded to RT |
| CVID*       | (72)       | 1    | NS                                                    | BMZL       | NR                 | 41/F    | Malaise, dyspnea and productive cough | IVIG, chlorambucil and prednisone | NR                    |
| CVID        | (73)       | 10/334| NS                                                   | NHL        | NR                 | NR      | NR                    | NR                      | NR                    |
| CVID        | (74)       | 10/416| NS                                                   | 1 DLBCL, 2 FL, 1 BL, 1 SLL, 1 EMZL, 3 NHL, 1 MM | NR     | NR                    | NR                      | NR                    |
| CVID        | (74)       | 23    | NR                                                   | NHL        | NR | NR29F, 11M       | NR | 11 died of lymphoma, 12 alive |
|             |            | 3     | NR                                                   | DLBCL      | NR | NR | 2 died of lymphoma, 1 also had severe lung disease, 1 alive |
|             |            | 4     | NR                                                   | HL         | NR | NR | 2 died of lymphoma, 2 alive |
|             |            | 5     | NR                                                   | BMZL       | NR | NR | All alive              |
|             |            | 1     | NR                                                   | MZL        | NR | NR | 3 no treatment, 2 chemotherapy |
|             |            | 1     | NR                                                   | Diffuse poorly differentiated | NR | NR | No treatment given, alive, Died of lymphoma |

(Continued)
### TABLE 1

**DISEASES OF IMMUNE DYSREGULATION**

| PID            | References | N  | Proposed mechanism                  | Cancer Specific mutations | Age/sex | Manifestation/course | Treatment | Outcome       |
|----------------|------------|----|-------------------------------------|--------------------------|---------|----------------------|-----------|---------------|
| Selective IgA deficiency | (75) | 1  | EBV associated                       | T-cell rich BCL          | NR      | McCL: monoclonal amplification of 98 base pairs in FR3A region of the IGH gene | 43/F      | Asymptomatic subcutaneous nodules in upper extremity, Enlarged axillary, mediastinal LN | Rituximab, Radiotherapy and local excision | Died of lymphoma |
| XLP1           | (76) | 3  | EBV associated                       | MZL: monoclonal amplification of 98 base pairs in FR3A region of the IGH gene | 33/M    | Lymphadenopathy       | R-CHOP    | CR            |
| XLP1*          | (77) | 1  | NS                                  | BL                        | 4/M     | Palpable abd mass, Malignant, poor appetite, failure to thrive | ETO, DVM, cyclophosphamide | Died at the age of 19 |
| XLP*           | (78) | 2  | EBV associated                       | BL                        | 1.6/M   | Lymphadenopathy, HS, Cerebellar tumor | Protocol LMB-84 | Died of hemorrage 6 m after stopping therapy, Relapse after 17 m, Died. |
| ITK deficiency* | (79) | 1  | EBV associated                       | HL                        | 5/F     | Cervical and inguinal lymphadenopathy | IFS, vinorelbine, etoposide, cytarabine, gemcitabine | Died of infection |
| ITK deficiency* | (80) | 2  | EBV associated                       | HL                        | 6/F     | Cervical and occipital lymphadenopathy | CHOP and anti CD20 Ab | Died of infection |
| ITK deficiency* | (81) | 1  | EBV associated                       | HL                        | 2.5/M   | Lung and Kidney       | CHOP and anti CD20 Ab | Died of infection |
| ITK deficiency* | (82) | 4  | EBV associated                       | HL                        | 5/F     | Lymphadenopathy        | Rituximab, VP-16, vinorelbine, GMC | Died of respiratory failure |
| ITK deficiency* | (83) | 3  | EBV associated                       | HL                        | 6/F     | Lymphadenopathy and Hepatosplenomegaly | Rituximab, VP-16, vinorelbine, GMC | Died of respiratory failure |
| ITK deficiency* | (84) | 2  | EBV associated                       | HL                        | 5/F     | Generalized LN, HS, nasal, concha tumor | Prednisone, procarbazine, vincristine, cyclophosphamide, ADM | Died of respiratory failure at 10 |
| PID | References | N | Proposed mechanism | Cancer | Specific mutations | Age/sex | Manifestation/course | Treatment | Outcome |
|-----|------------|---|--------------------|--------|-------------------|---------|---------------------|-----------|---------|
| CD70 deficiency* | (93) | 1 | EEBV associated | HL | Homozygous mutation in ITK 5q31–5q32. | 1/F | Retroperitoneal and abd. LN, HS | GNC, steroid, rituximab, HSCT | Died of ischemic brain injury |
| CD70 deficiency* | (93) | 1 | EEBV associated | HL | Homozygous c.250delT resulting in p.S84Pfs27X | 17/M | Peptic ulcer, gastritis, splenomegaly and lymphadenopathy | dexamethasone, bleomycin, vinblastine, and dacarbazine | CR after chemotherapy and radiotherapy. No relapse of HL. However, recurrent lymphoproliferative episodes. Well since HSCT. |
| CD70 deficiency* | (97) | 3 | EEBV associated | Pt1: HL | Homozygous c.555_557delCTT resulting in p.F186del | 2/M | Diffuse cervical lymphadenopathy | Initial OPPA and COPP ABVD | CR after ABVD/radiotherapy F/U at 16: CR |
| CD27 deficiency* | (93) | 5 | EEBV associated | Pt1: DLBCL | Homozygous c.G158A, p.C53Y | 2/F | NR | None | Died at 2 y |
| CD27 deficiency* | (93) | 5 | EEBV associated | Pt2: DLBCL | Homozygous c.G158A, p.C53Y | 22/F | NR | CHOP | Died at 22 |
| CD27 deficiency* | (93) | 5 | EEBV associated | Pt3: HL | Compound c.G264A, c.W8X, c.C319T, p.R107C | 15/F | Persistent cervical lymphadenopathy | None | Died at 20 y |
| CD27 deficiency* | (93) | 5 | EEBV associated | Pt4: HL | Homozygous c.G287A, p.C96Y | 7/F | NR | None | Died at 20 y |
| CD27 deficiency* | (93) | 5 | EEBV associated | Pt5: HL | Homozygous c.G287A, p.C96Y | 8/M | NR | CHOP, radiotherapy | Died during treatment |
| XMEN* (MAGT1 deficiency) | (93, 93) | 2 | EEBV associated | 1: BL | g.4313del/C | 7/M | 2nd malignancy at 14 | ABVD gemcitabine, vinorelbine, and brentuximab were followed by auto-HSCT | Relapse after ABVD, CR after HSCT |
| XMEN* (MAGT1 deficiency) | (93, 93) | 2 | EEBV associated | 2: HL | g.4604G>T | 17/NR | 2nd malignancy at 22 | | |
| XMEN* | (91) | 1 | EEBV associated (suspected) | DLBCL | c.712C>T, p.R238X | 57/M | Lymphadenopathy, HS and B-symptoms | RCHOP, RIGOMP | Died at 58 y from DLBCL |
| CTPS1 deficiency* | (93) | 1 | EEBV associated | HL | Homozygous c.555delC, p.Tyr186fsX2 | 15/M | Influenza-like symptoms | COP and ABVD | Alive at 17 y |
| CTPS1 deficiency* | (93) | 1 | EEBV associated | Pt1: NHL | NR | 6/F | NR | HSCT | Died at 6 y |
| CTPS1 deficiency* | (93) | 1 | EEBV associated | Pt2: NHL | NR | 1/M | NR | HSCT | Died at 2 y |
| CTPS1 deficiency* | (93) | 1 | EEBV associated | NS | NR | 1/F | No therapy received | | Died of disease progression after 6 m |
| Hypergammaglobulinemia | (41) | 1 | | DLBCL | | | | | |
| IL-10R deficiency | (34) | 5 | | | | | | | |
| IL-10R deficiency | (34) | 5 | | | | | | | |

(Continued)
TABLE 1

| PID | References | N | Defects in Intrinsically Inherited Immunity | Manifestation/course | Treatment | Outcome |
|-----|------------|---|------------------------------------------|---------------------|-----------|---------|
| PID |            |    | DEFECTS IN INTRINSIC IMMUNITY |                     |           |         |
| PID |            |    | Proposed mechanism & Proposed mechanism |                     |           |         |
| PID |            |    | Specific mutations |                     |           |         |
| PID |            |    | Ang/Sex |                     |           |         |
| PID |            |    | Age/sex |                     |           |         |
| PID |            |    | Induction Therapy |                     |           |         |
| PID |            |    | Treatment |                     |           |         |

**TABLE 1 | Continued**

X-linked PID (29-34). DLBCL (33%, n = 2) was the most common type of B cell lymphoma in this group, followed by BL, HL, unspecified NHL and immunoblastic B cell lymphoma. As with many of the other PIDDs, EBV association was present in all these types. It is relevant to note that only 33% patients (n = 2, HL and Burkitt lymphoma) had complete remission on follow-up, while the others died of disease progression or its complications. In a multi-center cohort of X-linked thrombocytopenia (XLt) patients, certain WAS genetic variants associated with XLt, a milder form of WAS, predisposed to a higher incidence of developing lymphoma suggesting that these patients would benefit from treatment with HCT (108).

**DiGeorge Syndrome (DGS)**

In this literature review, DGS did not appear to be associated with a high incidence of lymphomas, with only one reported case in a 10-month female who developed immunoblastic B cell NHL(35). Similar to other PIDDs this case was also associated with EBV infection. The patient manifested multi-system complications with hemiparesis due to a cerebral mass, mediastinal lymphadenopathy, liver and kidney involvement, and succumbed to the disease prior to initiation of therapy.

**Cartilage Hair Hypoplasia (CHH)**

CHH is a syndromic PIDD due to genetic defects in the RMRP gene and manifests with variable degree of immunodeficiency. While many patients who manifest with severe cellular immunodeficiency early in life may receive an HCT, patients with initially milder immunodeficiency may develop complications later in life, including malignancy. We identified 10 reported cases, with a median age of 29 years, equally divided between males and females. Majority of these cases were NHL (90%, n = 9) while the remaining (10%, n = 1) were HL. Interestingly, none of these were associated with EBV (36). This is in contrast to the 2 cases of adult CHH (male patients) in our center (unpublished, Mayo Clinic, Rochester), who were both EBV-positive and diagnosed in their 3rd to 4th decade of life. One of these patients was diagnosed with DLBCL after an incidental work-up of a lung nodule, while the other patient had MZL with recurrent fevers and night sweats. The patient with DLBCL was treated with R-CHOP and had CR, while the patients with MZL had recurrent disease, and was treated with rituximab. Therefore, like other PIDDs, CHH may also present with EBV-associated lymphomas, and it remains unclear if the EBV diagnosis could have been missed in other cases reported in the literature.

**Nijmegen Breakage Syndrome (NBS)**

In this review strategy, 9 studies with 97 cases of lymphomas in patients with NBS were identified (37-45). NBS is a syndromic DNA repair defect, and in these published reports, 76% (n = 74) of patients presented with unclassified NHL and DLBCL. Most cases (82%, n = 80) were EBV-negative. The underlying DNA repair defect puts these patients at high risk, unless they receive HCT early after diagnosis.

**Dyskeratosis Congenita (DC)**

Among the short telomere syndromes, while one would postulate high-risk of malignancy due to premature cellular senescence,
**TABLE 2** | Summary of T cell lymphomas in PIDDs.

| PID | References | Proposed mechanism | N | Cancer | Age/sex | Manifestation/course | Treatment | Outcome |
|-----|------------|--------------------|---|--------|---------|----------------------|------------|---------|
| **PREDOMINANTLY ANTIBODY DEFICIENCIES** | | | | | | | | |
| CVID | (97) | Immune dysregulation | 1 | DLL | 52/M | RUQ tenderness, early satiety, HS, erythematous skin papules, progressive refractory anemia, and recurrent bacterial infections | Chlorambucil and Prednisone | Poor response, died in 2 years. |
| CVID | (98) | Immune dysregulation | 1 | PTQL | 57/M | Fever, night sweats, and progressive refractory anemia, tender inguinal lymphadenopathy | ProMACE CytaBOM | CR after 6 cycles |
| CVID | (99) | NS | 1 | PTQL | 32/F | Persistent cytopenia, progressive neurologic disease presenting as a polyradiculopathy with aseptic lymphocytic meningitis | cranial radiation, systemic and intra-thecal chemotherapy | Symptoms progressed. Died in few months. |
| IgA deficiency | (100) | Immune dysregulation | 1 | PTQL | 24/M | 4 years after PID diagnosis: liver failure, abdominal lymphadenopathy, pancytopenia, and recurrent bacterial infections and increasing pulmonary infiltrates | None. Diagnosis on autopsy. | Died of pulmonary failure before diagnosis |
| XLA | (101) | Chronic antigenic stimulation | 1 | GCTCL | 33/M | Generalized asymptomatic papulonodular eruption No lymphadenopathy/organomegaly | NR | NR |
| XLA | (102) | Immune dysregulation | 1 | GCTCL | 68/M | Progressive generalized papules, plaques, and tumors. Occult IgA def diagnosed after presentation. | cyclophosphamide, methotrexate, etoposide, and dexamethasone | CR followed by recurrence and eventual death in 5 years |
| IgA deficiency | (102) | Immune dysregulation | 1 | GCTCL | 44/M | progressive, asymptomatic red papules and nodules on his trunk and extremities. | Bexarotene Gemcitabine | Relapse and disease progression |
| IgA deficiency | (41) | NS | 2 | Pt1: ALCL, Pt2: TNHL | 11/M | | NHL-BFM | CR, LFU +3.5 years |
| CVID | (71) | NS | 4/247 | 4 T-cell | NR | | NHL-BFM | CR, LFU +3.5 years |
| CVID | (3) | NS | 1/416 | 1 PTCL | NR | | NHL-BFM | CR, LFU +2.75 years |
| APDS | (52) | NS | 1/53 | ALCL | NR | | NHL-BFM | CR, LFU +2.75 years |
| Hypogammaglobulinemia | (41) | NS | 1 | ALCL | 15/M | | NHL-BFM | CR, LFU +2.75 years |

(Continued)
### COMBINED IMMUNODEFICIENCIES WITH ASSOCIATED OR SYNDROMIC FEATURES

| PID | References | Proposed mechanism | N  | Cancer | Age/sex | Manifestation/course | Treatment | Outcome |
|-----|------------|--------------------|----|--------|---------|----------------------|-----------|---------|
| NBS | (44)       | Chronic antigenic stimulation | 5/57 | TNHL | NR      | NR                   | NR        | 15 out of 22 patients (B and T lymphomas) died, most at the beginning of the study, but 7 were clinically stable after early diagnosis and successful treatment |
|     |            | Chronic antigenic stimulation | 2/57 | TLBL | NR      | NR                   | NR        |         |
| NBS | (45)       | NS                  | 21/149 | TNHL | NR      | NR                   | NR        | 44% of all patients were in remission, 54% died due to disease progression |
| NBS | (103)      | EBV associated      | 1   | TLBL | 10/F    | Fever, generalized lymph node enlargement, hepatosplenomegaly and mediastinal mass | BFM90 protocol | Alive 7 years later |
| NBS | (37)       | NS                  | 9   | TLBL | 10/F    | NR                   | BFM90     | Died of disease after protocol |
|     |            |                     |     | TLBL | 8/F     | NR                   | BFM90     | Died of relapse during maintenance |
|     |            |                     |     | TLBL | 16/M    | NR                   | BFM90     | Died of relapse during maintenance |
|     |            |                     |     | TLBL | 12/M    | NR                   | BMF-90 followed by chemotherapy (ICE) | Died of organ failure caused by sepsis |
|     |            |                     |     | ALT  | 8/F     | NR                   | BMF-90 followed by individualized chemotherapy | Died of disease |
|     |            |                     |     | TLBL | 7/F     | NR                   | EURO-LB 02 protocol | Alive disease-free |
|     |            |                     |     | TLBL | 3/M     | NR                   | EURO-LB 02 protocol | Alive disease-free |
|     |            |                     |     | TLBL | 9/M     | NR                   | EURO-LB 02 protocol | Alive with disease |
|     |            |                     |     | TLBL | 19/F    | NR                   | EURO-LB 02 protocol | Died of relapse during maintenance |
|     |            |                     |     | TLBL | 18/M    | 2nd malignancy: AML | EURO-LB 02 protocol | Death because of 2nd malignancy (AML), 3.5 years after diagnosis |
|     |            |                     |     | TLBL | 16/M    | NR                   | EURO-LB 02 protocol | CR 1 year after diagnosis |
|     |            |                     |     | TLBL | 4/M     | 2nd malignancy: TLBL, 14 years after diagnosis | NHL-BFM90 | CR after treatment in accordance to GMALL protocol for 2nd malignancy |
|     |            |                     |     | TLBL | 6/F     | NR                   | EURO-LB 02 protocol | CR 2.4 years after diagnosis |
|     |            |                     |     | TLBL | 8/M     | NR                   | ALL-BFM-MR protocol | CR 1.7 years after diagnosis and 1 year after SCT |

(Continued)
### TABLE 2 | Continued

| PID                  | References | Proposed mechanism                        | N                | Cancer       | Age/sex | Manifestation/course         | Treatment                          | Outcome                        |
|----------------------|------------|-------------------------------------------|------------------|--------------|---------|-----------------------------|-----------------------------------|--------------------------------|
| NBS                  | (39)       | Defective antitumor immunosurveillance    | 2/26             | Pt6: TLBL   | 16/M    | NR                          | NHL-BFM95                         | Death 1 year after diagnosis    |
|                      |            |                                           |                  | Pt11: TLBL  | 16/M    | NR                          | NR                                | Death at 18 years                |
| NBS                  | (40)       | NS                                        | 3                | Pt2: TNHL   | 24/M    | NR                          | NR                                | Death at 27 years from sepsis    |
|                      |            |                                           |                  | Pt11: TLBL  | 8/F     | Cervical LN                 | NR                                | Died at 11 years                 |
|                      |            |                                           |                  | Pt2: TLBL   | 16/M    | Cervical LN                 | NR                                | Died at 18 years                 |
|                      |            |                                           |                  | Pt3: TLBL   | 12/M    | Cervical LN                 | NR                                | Died at 13 years                 |
| Ataxia Telangiectasia| (38)       | NS                                        | 1                | Pt1: TLBL  | 0.5/M   | 2nd malignancy; B-NHL after 3.5y | NHL-BFM96 modified                | Death of second malignancy       |
| Ataxia Telangiectasia| (41)       | NS                                        | 1                | TNHL        | 0.5/M   | 2nd malignancy; low-grade B-NHL | Non-B therapy, induction with 50% dosage, then reduced maintenance; omission of therapy after 7 months from severe toxicity | Reached CR initially; died of 2nd malignancy after 3.75 years |                     |
| NBS                  | (4)        | Defective DNA repair                      | 3                | Pt1: TLBL   | 5/M     | NR                          | NHL-BFM95, phase I protocol, nonmyeloablative conditioning, HSCT | CR 1, alive disease-free for 1.4 years |
|                      |            |                                           |                  | Pt2: PTCL   | 16/M    | NR                          | CHOP–CHOP–ICE–DHAP–DHAP–DexaBEAM | Died of disease at 5 months after the diagnosis |
|                      |            |                                           |                  | Pt3: TLBL   | 14/M    | NR                          | NHL-BFM95, protocol I, full dosage | Death of sepsis in PR after 7 weeks of therapy |

### IMMUNODEFICIENCIES AFFECTING CELLULAR AND HUMORAL IMMUNITY

| PID                  | References | Proposed mechanism                        | N                | Cancer       | Age/sex | Manifestation/course         | Treatment                          | Outcome                        |
|----------------------|------------|-------------------------------------------|------------------|--------------|---------|-----------------------------|-----------------------------------|--------------------------------|
| CID                  | (4)        | Impaired Immune function                  | 1                | TLBL         | 8/M     | 9                           | NHL-BFM95, full dosage             | Death of sepsis in CR 2 at 2 years after the diagnosis |

### DISEASES OF IMMUNE DYSREGULATION

| PID                   | References | Proposed mechanism                        | N                | Cancer       | Age/sex | Manifestation/course         | Treatment                          | Outcome                        |
|-----------------------|------------|-------------------------------------------|------------------|--------------|---------|-----------------------------|-----------------------------------|--------------------------------|
| CD27 deficiency       | (88, 104)  | EBV associated                            | 1                | Pt1: TQL    | 16/M    | Oral ulcers, uveitis, chronic EBV viremia, and EBV-related LPD progressing to T-cell lymphoma | Rituimab, R-CHOP, cord HSCT | Alive                          |
| Hypergammaglobinemia  | (41)       | NS                                        | 1                | PTQL         | 2/F     |                             | Non-B therapy, induction, followed by maintenance | Still on maintenance therapy in PR for 2 years |

ALT, (angioimmunoblastic T cell lymphoma); AML, (acute myeloid leukemia); CID, (combined immunodeficiency); CVID, (Common variable immune deficiency); DLL, (diffuse lymphocytic lymphoma); CR, (complete remission); F, (female); GCTCL, (granulomatous cutaneous T-cell lymphoma); HS, (hepatosplenomegaly); LN, (lymph nodes); M, (male); NR, not reported; NBS, (Nijmegen breakage syndrome); NHL-BFM, (Non-Hodgkin Lymphoma-Berlin-Frankfurt-Münster); NS, not specified; PR, (partial remission); ProMACE, (prednisone, doxorubicin, cyclophosphamide, etoposide, methotrexate, leucovorin); P, (patient); PTCL, (peripheral T-cell lymphoma); R-CHOP, (Rituximab + cyclophosphamide, doxorubicin, vincristine, and prednisone); RUQ, (right upper quadrant); TLBL, (T lymphoblastic lymphoma); XLA, (X-linked agammaglobulinemia); TQL, (T cell lymphoma).
this literature search only yielded a single case of an adult DC patient with HL not associated with EBV (46). The treatment strategy included combination chemotherapy and radiation, which likely was not appropriate in the context of the patient’s underlying genetic defect, and presumed radiosensitivity, as the patient subsequently developed a gastric carcinoma and died of the disease. Short telomere syndromes are known to be associated with radiosensitivity, and therefore, radiation therapy is probably not a recommended treatment modality in this group, as well as in the patients with DNA repair defects.

**Schimke Immuno-Osseous dysplasia**

We identified 3 studies, with 5 cases of B cell lymphoma (47–49). EBV association was seen in a single case (20%, n = 1). Outcome data was given for two patients, both of whom died with complications soon after starting chemotherapy.

**CHARGE Association With Hyper IgM Syndrome**

We identified one report of a 5-year-old girl, with nonclassical CHARGE association and elevated IgM levels who developed bilateral extranodal (ocular) MZL. She was treated with topical interferon alpha with subsequent complete resolution of disease (50).

**IUIS: Predominantly Antibody Deficiencies**

In this literature review, we identified 27 studies, which reported B cell lymphomas in 208 patients with predominantly antibody deficiencies. The median age at presentation was 46 years (range: 2–76 years) with a gender distribution of 34% (n = 71) female, 13% (n = 27) male, and 53% (n = 110) NS.

**Common Variable Immune Deficiency (CVID)**

Twenty-two studies of 192 CVID patients with B-cell lymphoma are presented in Table 1 (3, 54–74). Common lymphomas included unclassified NHL (32%, n = 62), MALT lymphoma (EMZL) (7%, n = 14), DLBCL (5%, n = 9), and HL (4%, n = 8). Of these, 31% (n = 60) cases appeared to be associated with EBV infection. Possible mechanisms of lymphomagenesis in these different cohorts included chronic antigenic stimulation and defective immune surveillance. The treatments of choice in these patients included surgical resection and/or radiotherapy with chemotherapy. Common Variable Immunodeficiency (CVID) is the most common adult humoral immunodeficiency, both in US and European studies. There are several reports documenting an increased risk of lymphoma in these patients. In a large cohort of 176 patients with CVID, an increased incidence of lymphoma (obs = 4; SIR = 12.1; 95% CI = 3.3–31.0) was noted (54). In an ESID (European Society for Immunodeficiencies) registry study of 2,212 CVID patients, a subset (n = 902) analysis identified 3% of patients with lymphoma (106). However, in another study from a single center, which followed 473 CVID patients over four decades, the incidence of lymphoma was higher at 8.2% (74).

**Selective IgA Deficiency**

Three studies reported three cases of selective IgA deficiency with B cell lymphoma; an adult patient with apparent selective IgA deficiency who presented with a primary cutaneous MZL, a 38-year-old male with unclassified NHL and a 2-year-old boy
with Burkitt-like lymphoma (41, 54, 75). It is relevant to note that a combined Danish and Swedish study of 386 patients with IgA deficiency did not show an increased risk for cancer (standardized incidence ratio = 1.0) (54).

**Activated Phosphoinositide 3-Kinase D Syndrome (APDS)**

Nine patients with gain of function (GOF) mutation in PIK3CD gene (APDS) developed B cell lymphoma in the three studies identified in this review (51–53). DLBCL was the most common type (33%, n = 3). An EBV association was not seen in these particular cases.

**Other Ig Deficiencies**

Seidemann et al. reported four cases of B cell lymphoma in different Ig subclass deficiencies (excluding selective IgA deficiency) (41). Seventy-Five Percent (n = 3) had Burkitt lymphoma (BL). Two died during treatment with chemotherapy, two were alive and in complete remission at last follow up.

**IUS: Diseases of Immune Dysregulation**

In this category, 42 cases from 20 studies were identified, and of these, 76% (n = 32) had an association with EBV (41, 76–94). The median age of the reported cases was 5 years (range: 1–33 years), 62% (n = 26) were male, 31% (n = 13) female and 7% (n = 3) were NS. HL (48%, n = 20) was the most common subtype in these disorders of immune dysregulation, followed by DLBCL (29%, n = 12), BL (12%, n = 5), unspecified NHL (7%, n = 3) and composite lymphoma—FL, DLBCL, HL (2%). Specific examples are discussed further.

**X-linked Lymphoproliferative Syndrome Type 1 (XLP-1)**

In patients with X-linked lymphoproliferative syndrome type 1 due to genetic defects in SH2D1A, there were 3 studies with six patients who developed B cell lymphoma [4 BL, 2 DLBCL (77–79)]. The median age at diagnosis of lymphoma was 5 years (range: 1–14 years), and of these cases, 50% (n = 3) were EBV-associated and 50% (n = 3) had no apparent EBV association. Since XLPI is associated with a defective immune response to EBV related to impaired cellular cytotoxicity it is not unexpected that there would be impaired immune surveillance in these patients (109). The two patients who had a DLBCL not related to EBV presented with a testicular mass and right chest mass, respectively. In the cases with the BL, clinical presentation involved lymphadenopathy and palpable abdominal mass/obstruction or cerebellar tumor. With the exception of a single case, all patients died within 5 years of diagnosis regardless of treatment modality used.

**Interleukin-2-Inducible T-Cell Kinase (ITK) deficiency**

Patients with ITK deficiency have an intrinsic susceptibility to EBV. In six studies, 13 patients with ITK deficiency (Table 1) who developed B cell lymphoma were identified, and all were associated with EBV (80–85). The most common was HL (84%, n = 11) followed by NHL (7%, n = 1) and DLBCL (7%, n = 1). The median age at presentation was 5 years (range: 1–6) with 54% (n = 7) female and 46% (n = 6) male, presenting clinically with lymphadenopathy and hepatomegaly. The treatment of choice was chemotherapy and HCT.

**Autoimmune Lymphoproliferative Syndrome (ALPS)**

While there are several genetic defects associated with ALPS or ALPS-like disease, the most frequent genetic defect associated with a classic ALPS-like phenotype is heterozygous germline pathogenic variants in the FAS gene. In Table 1, there was a single report an EBV-associated composite lymphoma (FL, DLBCL, HL) in an adult male with ALPS, which was treated with R-CHOP resulting in CR (76).

**IL10-R Deficiency**

Monogenic inflammatory bowel disease (IBD) can be associated with complex presentations, and patients with genetic defects in the IL-10 receptor (IL10RA and IL10RB) have particularly severe disease with additional complications. A single case report (110) and a case series has reported DLBCL in 5 patients with IL10R deficiency (94). There was no EBV association noted in any of these cases, and the median age of developing lymphoma was 5 years (range: 5–6 years). Interestingly, all patients in these series were male. Chemotherapy with COP (cyclophosphamide, vincristine, prednisone), COPADM (cyclophosphamide, vincristine, prednisone, doxorubicin, methotrexate), CYM (cytarabine, methotrexate), and ICE (ifosfamide, carboplatin, etoposide) was used with variable success. Among the five patients, two died due to disease progression during treatment, while three who received HCT remained alive and in remission on follow-up. It is evident that in this context, HCT is not only curative but may very well prevent the occurrence or recurrence of lymphoma (111).

**CD70 Deficiency**

B cell lymphoma was reported in four male patients under the age of 20 with CD70 deficiency across two studies (86, 87). All patients presented with HL, associated with EBV infection and were managed with chemotherapy and radiotherapy. Two patients underwent HCT and complete remission was achieved in all cases.

**CD27 Deficiency**

We identified one study reporting five cases (mostly females) with CD27 deficiency who developed B cell lymphoma (88). Three patients were diagnosed with HL, and two with DLBCL. All were related to EBV infection. Only two patients with HL treated with the EuroNet-PHL-C1 (EuroNet-Pediatric Hodgkin's Lymphoma Group-C1) protocol and ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) plus radiotherapy respectively were alive and in complete remission.

**XMEN (MAGT1) Deficiency**

Four studies with four patients were reported to develop B cell lymphoma in the context of MAGT1 deficiency (89–92). All were males with EBV-associated lymphomas. The ages ranged from 7 to 57 years, and the distribution of B cell lymphomas included 2 HL, 1 BL, and 1 DLBCL.
CTP Synthase 1 (CTPS1) deficiency
One study reported two cases with EBV-associated unspecified NHL in patients with CTPS1 deficiency (93).

IUIS: Defects in Intrinsic and Innate Immunity
WHIM (Warts, Hypogammaglobulinemia, Immunodeficiency, and Myelokathexis) Syndrome
WHIM syndrome is caused by gain-of-function defects in the CXCR4 gene frequently associated with severe neutropenia and variable degree of immunodeficiency. There are two reports (Table 1) of B cell lymphoma (type not specified) in two adult patients with WHIM syndrome (95, 96). Both were associated with EBV infection leading to lymphoproliferation and ultimately lymphoma. Treatment in both cases was with CHOP chemotherapy, and one patient had a CR, while the other patient who presented with intestinal lymphoma had no response and died of intestinal perforation.

T CELL LYMPHOMAS IN PIDS
The incidence of T cell lymphomas is infrequent in PIDDs (Table 2). In this particular literature review, 74 patients were identified through 20 different reports. The types of T cell lymphomas identified included T cell non-Hodgkin lymphoma (TNHL) 36%, T cell lymphoblastic lymphoma (T-LL) 32%, peripheral T cell lymphomas (PTCL) 9%, granulomatous cutaneous T-cell lymphoma (G-CTCL) 4%, anaplastic large cell lymphoma (ALCL) 4%, and T cell diffuse lymphocytic lymphoma (T-DLL) 1%. Of these cases, 41% (n = 30) were male, 10% (n = 10) were females and 46% (n = 34) did not report gender. The median age at the diagnosis of lymphoma was 13 years (range 0.5–68 years). It is interesting and relevant to note that the cases of T cell lymphomas were mostly observed in patients with predominantly antibody deficiencies or combined immunodeficiencies with associated or syndromic features. Only a single report is available of a patient with a combined immunodeficiency (CID) (Table 2), who developed T-LL and was treated with full dose NHL-BFM95 on a phase1 clinical trial, and was in CR but subsequently died of sepsis (4).

IUlS: Predominantly Antibody Deficiencies
In patients with humoral immune defects, there were 10 studies with 17 patients reported (Table 2). The types of T cell lymphomas observed were PTCL (29% n = 5), G-CTCL (18%, n = 3), ALCL (18%, n = 3), T-LL (5% n = 1), and TNHL (5%, n = 1). The median age at diagnosis was 32 years (range: 2–68 years) with a distribution of males (59%, n = 10), females (6%, n = 1) and NS (35%, n = 6).

Common Variable Immunodeficiency (CVID)
Of the patients with humoral defects, 53% (n = 9) had CVID across six studies, and the main types of T cell lymphomas included were PTCL, T-LL, G-CTCL, and 4 unspecified T-cell lymphomas (3, 71, 97–99, 102). The treatment modalities used include Prom ACE (prednisone, doxorubicin, cyclophosphamide, etoposide, methotrexate, leucovorin), CytBOM (cytarabine bleomycin, vincristine, methotrexate), radiation, systemic and intra-thecal chemotherapy. A single CVID patient presented with G-CTCL, which relapsed and progressed after treatment with bexarotene and gemcitabine. Another CVID patient developed T-LL and had a poor response to chlorambucil and prednisone and succumbed to disease within 2 years.

Selective IgA Deficiency (sIgAD)
As with B cell lymphoma, there were three reports of four patients with sIgAD who developed T cell lymphoma (G-CTCL, PTCL, ALCL, TNHL) (41, 100, 102). All were males, and the diagnosis was made by autopsy in one patient, while the diagnosis of occult IgA deficiency was made in the second patient after the development of malignant disease. Though this patient was treated with chemotherapy with apparent CR, there was subsequent relapse of disease and mortality within 5 years. In patients classified as having sIgAD and malignant disease, it remains an open question as to whether there was a more severe underlying immunological defect that was not identified at the time.

Hypogammaglobulinemia
Seidemann et al. reported a case of 15-year-old male with hypogammaglobulinemia who developed ALCL (41). Complete remission was achieved on treatment with chemotherapy. Last follow up was almost three years after diagnosis. A molecular etiology for the hypogammaglobulinemia was not available in this patient.

XLA
In the 2 patients reported with XLA, the types of T cell lymphoma observed were G-CTCL and PTCL (101, 102).

IUIS: Combined Immunodeficiencies With Associated or Syndromic Features
In this category, we identified nine studies with 54 patients. Median age was 10 years (0.5–24). Similar to other categories with T cell lymphomas, males had a higher percentage (33%, n = 18)
compared to females (15%, \( n = 8 \)) and 52% (\( n = 28 \)) were NS. TNHL (52%, \( n = 28 \)) was the most common type of TCL followed by TLBL (44%, \( n = 24 \)).

Nijmegen Breakage Syndrome (NBS)
Similar to B cell lymphomas (BCL) in NBS, there are reports of T cell lymphoma (TCL) in this group of patients. In Table 2, there are eight studies with 52 patients, all under the age of 20 (4, 37–40, 44, 45, 103). The underlying mechanism for development of malignant disease is the same as for BCL and related to defects in DNA repair. The commonly used chemotherapy protocols in these patients included NHL-BFM-90, NHL-BFM-95, and EURO-LB 02.

AT
We identified two studies reporting two cases of TCL in AT patients (38, 41). A 6-month-old boy was diagnosed with TLBL and treated with a modified NHL-BFM 86 regimen. He developed B-NHL at the age of four leading to death. The second patient was also a 6-month-old boy who developed T-NHL and achieved complete remission initially, but like the first patient died at the age of four due to a second malignancy (B-NHL).

DISCUSSION
In this section, we discuss the mechanisms responsible for lymphomagenesis in the various inborn errors of immunity and provide an overview of the treatment.

DEFECTS IN IMMUNE RESPONSES THAT PREDISPOSE TO LYMPHOMAGENESIS IN PIDDs
The complex immune mechanisms and their interplay that predispose to neoplastic transformation of B or T cells and development of lymphomas in PIDD patients has not been fully elucidated. However, it is expected that the etiology in most cases is multifactorial and related to a dynamic regulation of immune response and environmental triggers (Figure 3). An underlying intrinsic susceptibility to DNA damage in some of these PIDDs, may provide a substrate for uncontrolled cell growth, impaired apoptosis of damaged cells, premature cellular senescence, all of which may be compounded by increased antigenic stimulation of adaptive lymphocytes by viruses, such as EBV (112). This uncontrolled stimulation in the setting of altered immune checkpoints and immune dysregulation characterized by T cell exhaustion, defective anti-tumor immune surveillance and overproduction of inflammatory cytokines provides a fertile setting for neoplastic transformation and lymphoproliferation (Figure 3).

Defective DNA Repair
DNA integrity is constantly challenged at various levels as part of physiological processes. In lymphocytes, there is particular susceptibility specifically related to intrinsic mechanisms that are part of the immune diversity generation apparatus, such as V(D)J recombination, class switch recombination (CSR), and somatic hypermutation (SMH) (113). These intrinsic “stress points” coupled with other factors, including exposure to internal mutagens (e.g., endogenous metabolites) and external factors such as ultraviolet rays, ionizing radiation and chemicals (107) sets the stage for development of dysregulated cellular proliferation in B or T cells. Therefore, it is not surprising that normally there is a highly conserved DNA repair system orchestrated by a network of enzymes, which constantly assesses and detects DNA damaging lesions, modifies or removes damaged DNA, and reconstitutes the integrity of DNA through nucleotide resynthesis and ligation (114). When these checks and balances fail in the context of monogenic defects, it promotes the development of lymphoid tumors (113). Patients with premature cellular senescence related to shortened telomeres not only have an intrinsic susceptibility to DNA damage-inducing stimuli but also may have impaired apoptosis of damaged cells, which in turn may promote lymphoproliferation.

Role of Viral Infections and Defective Immune Surveillance, and Immune Dysregulation
Several of the documented PIDDs increase susceptibility to viral infections such as EBV, human papilloma virus (HPV), human herpes virus-6 (HHV-6), HHV-8, human T-cell lymphotropic virus (HTLV), Kaposi sarcoma–associated virus (KSV), and other viruses due to defective immune surveillance and immune dysregulation (115). Among these viruses, EBV represents the biggest threat because of its high prevalence (95%) and ability to transform epithelial cells, B cells, T cells and NK cells (116).

In the majority of cases, EBV virions entering through the oro-pharynx infect epithelial cells and B cells via the CD21 receptor. From a host immune system standpoint, NK cells and antigen-specific CD8+ T-cells are the main defense against primary EBV infection. Therefore, if EBV-infected B cells escape the cellular immune response, it can provoke an inflammatory outburst, resulting in cellular hyperproliferation and abnormal cell survival eventually leading to EBV-associated lymphoproliferative disorders (EBV-LPDs). EBV-LPDs consist of virus-associated hemophagocytic syndrome, non-malignant and malignant B-cell LPDs including non-Hodgkin and Hodgkin’s types of B lymphomas and rarely EBV-positive T/NK cell lymphoma (117). The critical role of NK and T cells is demonstrated by the fact that combined B and T cell deficiency PIDDs account for approximately 2/3rd of EBV-associated LPDs in PIDDs, whereas defects in innate immunity do not significantly increase the risk of EBV-associated LPDs (116). Thus, underlying genetic defects in SH2D1A (SAP–XLP-1), ITK, MAGT1, CD27, CD70, CTPSI, RASGRP1, CORO1A and others account for the majority of EBV-LPDs.

The lack of adequate immune surveillance in the context of immune dysregulation is not uncommon in PIDDs, and though these cannot be exhaustively discussed here, failure of both innate (NK cells) and adaptive (T cells) immune cellular mechanisms facilitate viral escape and subsequent viral transformation of lymphocytes with poor cytotoxic clearance of virally-infected cells (89, 117). On the other
hand, in certain other PIDDs, for example, the IL-10 receptor defects, there is production of pro-inflammatory cytokines due to the lack of IL-10-based regulation, and NFκB activation, with defective intra-tumoral CD8+ T cell immune surveillance and impaired cytotoxicity. This results in B cell proliferation and accumulation of somatic mutations (94, 111). Therefore, this is associated with a non-EBV-associated lymphoproliferation.

**Chronic Antigenic Stimulation**

Patients with PIDDs are more likely to develop persistence of antigens, and therefore ongoing stimulation of effector immune
and subsequently eliminate non-self-antigens (pathogen-infected and/or transformed cells). Sustained antigenic stimulation, in the context of cellular and systemic immune compromise, is likely to increase T cell exhaustion with progressive loss of cytokine secretion (IL-2, TNF-α), impairment of IFN-γ production, and in extreme cases premature apoptosis of CD8+ T cells (118). This quantitative and qualitative loss of the CD8+ T cell immune response against tumor cells eventually results in the development of lymphomas, and another plausible mechanism for tumor development in PIDDs.

**Altered Immune Checkpoints**

One of the primary mechanisms by which tumors escape the immune system is by engaging immune checkpoints (119), which is why immune checkpoint inhibitors (ICIs) were approved for the treatment of cancers and are now used in 14 different types of cancer (120). This issue is relevant to the lymphomas, which develop in PIDDs as it has been shown that PD-L1 protein is overexpressed in most EBV-associated tumors (121). Further, copy number variations (CNVs) at 9p24.1 have also been reported, and this is a locus, which harbors PD-1 (122). However, only one of two studies found amplifications of chromosome 9p via array CGH (comparative genomic hybridization) in EBV+ DLBCL (123). These findings raise the possibility that EBV+ DLBCL evades immune surveillance by selectively targeting the PD1/PDL pathway. Therefore, there may be some value to using immune checkpoint inhibitors in PIDDs for the treatment of lymphoma, and this raises the need for clinical trials in this area.

**TREATMENT OF B AND T CELL LYMPHOMAS IN PIDDs**

**Clinical Presentation, Diagnosis and Staging**

PIDD patients often present with advanced disease, and extranodal sites of disease, including bone marrow, liver, and spleen, and the presence of B-symptoms is quite common. There is no difference in how the diagnosis of lymphoma is established, whether in in PIDDs or non-intrinsic lymphoid malignancies, and it usually involves tissue biopsy, most frequently of lymph nodes.

Clinical evaluation should include standard workflow of history and physical, complete blood count with differential, liver and kidney function and baseline pulmonary function test for adult patients, if they will undergo bleomycin-containing regimens in the context of HL. Additional work-up to assess the degree of immune impairment, based on underlying genetic defect is essential for this patient population, and should include evaluation of radiosensitivity (especially if the genetic defect is known to predispose to this) so that appropriate treatment regimens can be formulated. Principles of diagnostic imaging may be extrapolated from imaging recommendations for Hodgkin’s lymphoma in HIV patients, which suggests 18FDG-PET with integrated or concurrent CT (computerized tomography) of the neck, chest, abdomen, and pelvis. Since 18FDG-PET imaging has not been validated in this setting, it is unclear whether a bone marrow biopsy can be omitted. The interpretation of 18FDG-PET scan can be challenging in presence of concurrent infections, which is not uncommon in these patients (124).

**Treatment Options**

While there are no specific treatment options for lymphoma in PIDD patients, radiation-based therapies should be avoided in patients with known genetic defects that predispose to radiosensitivity. Most frequently standard treatment options are based on type of lymphoma, such as B or T cell, indolent, aggressive or very aggressive and patient-related characteristics such as age, comorbidities, immune status, and degree of immune compromise. While there are no large or randomized studies to confirm this, small series and case reports show that response to the treatment and prognosis is inferior in PIDD patients when compared to non-PIDD patients, largely related to their inability to tolerate standard chemotherapy, and susceptibility to life-threatening infections (25). HCT remains the only viable curative option for many of these diseases, though its efficacy of HCT is variable across different PIDDs. For example, the role of HCT in severe combined immune deficiencies (SCID) is well established and it has been consistently replicated (125). HCT is not a standard treatment of choice in CVID, especially those without a molecular defect, though it may be warranted in certain cases depending on the presentation and associated co-morbidities. In circumstances, of a specific molecular diagnosis replacing or clarifying the underlying CVID, HCT may be the most optimal long-term treatment of choice, even though more targeted therapies may be available. HCT for CVID was reported in a multicenter experience for 25 patients transplanted at 14 centers in Europe, the US, and Japan, and though it may be considered for lymphoma in this context, the risk of transplant-related mortality (TRM) should be clearly weighed against the potential benefits (126). Several retrospective studies have reported outcomes of HCT as across a range of PIDDs, including SCID (127), and Wiskott Aldrich Syndrome (128). Only case reports or small case series are available for successful treatment in patients with other PIDDs such as GATA2 haploinsufficiency, IL-10 receptor or XIAP deficiencies. Despite the limited experience, data strongly favors the early use of HCT in the setting of IL-10 receptor deficiency (111). Recently, a retrospective case series of 29 adult patients with a variety of PIDDs (mean age: 24 years, range: 17–50 years) treated with reduced intensity conditioning (RIC)-HCT was published. This study reported an overall survival of 85.2% at 3 years (129). These data provide support for moving forward with HCT in adult PIDD patients. As such, in addition to the treatment of lymphomas, HCT can be lifesaving in patients with PIDDs who develop very severe complications, including susceptibility to life-threatening infections, bone marrow failure, autoimmune and autoinflammatory diseases, other malignancies, and hemophagocytic syndrome. Despite all these potential benefits, it remains to be ascertained as to whether early HCT can reduce the risk of developing lymphoma in these PIDD patients in the long term.
There is no consistent evidence to support the use of newer immunotherapies for treatment of lymphoma in PIDDs but these therapies hold significant mechanistic promise for personalized, chemotherapy-free treatments. Potential immunotherapy options include monoclonal antibody-based immunotherapy (e.g., Rituximab, Obinutuzumab, Epratuzumab), conjugated antibodies (Brentuximab Vedotin), Bi-Specific T cell engaging (BiTE) antibodies (Blinatumumab), Anti-PD1 (Pembrolizumab, Nivolumab), Anti PDL-1 (Atezolizumab and Darvulamab), and anti-CTLA4 checkpoint inhibitors (e.g., Ipilimumab). The role of adoptive T cell therapies such as chimeric antigen receptor (CAR) T-cells remains uncertain at this point (130). While these targeted therapies may have value, they may also pose an increased risk as a result of immune manipulation in the context of an underlying immune deficiency or immune dysregulation.

While there are no reports for successful use of immune checkpoint inhibitors or BiTE antibodies, complete remission with Rituximab and Brentuximab Vedotin was reported in an adult female patient with CVID-associated classic HL, while two other cases of pediatric CVID-associated HL succumbed to severe infection related to chemotherapy (61).

CONCLUSIONS

Though this is not a comprehensive summary of malignancies in PIDDs, or even lymphoproliferative disease in this area, this review summarizes the Medline-indexed published reports of B and T lymphomas in patients with PIDDs. This report highlights the diversity of malignant lymphoproliferative disorders in setting of PIDDs, and its associated challenges of diagnosis and treatment. The pathological classification and nomenclature for the lymphoid malignancies with variably reported and postulated underlying mechanisms were inconsistent and inadequate for many of these published reports. A wide range of treatment options were utilized, and response rate was highly variable suggesting an empirical approach rather than a systematic and tailored treatment regimen, based on underlying genetic defect, and degree of immunological impairment. HCT and gene therapy (where available) remains the best treatment option for many, but not all of these patients, and should be promptly initiated after diagnosis, particularly in some conditions, such as SCID, WAS, IL10 receptor deficiency among others. HCT, as a therapeutic option, remains significantly under-utilized in adult patients, likely related to inadequate awareness among adult hematologists, and these patients may benefit from increased utilization of HCT in appropriate settings. We highlight the significant need of unifying nomenclature, pathological analysis, and assessment of mechanisms of lymphomagenesis in these patients to develop better and more personalized treatment regimens. Also, there is a considerable urgency to conduct clinical trials to develop evidence-based treatment plans that considers the underlying immunodeficiency rather than using approaches extrapolated from non-PIDD settings (131). It is recognized that there has been a recent effort to standardize classification and nomenclature in immunodeficiency-associated malignant LPDs, but this is largely focused on secondary immunodeficiency disorders, in contrast to primary, though presumably some of the same standards could be applied (132), but this should be undertaken specifically for PIDDs, to fully understand the similarities and differences in pathology.

AUTHOR CONTRIBUTIONS

All authors designed the study. IR and WF performed the literature search, conducted data extraction of relevant studies, and wrote the first draft of the manuscript. MP and RA critically reviewed the literature search and made revisions in the manuscript. All authors read and approved the final version of the manuscript.

REFERENCES

1. Kobrinsky L, Powell RW, Bowen S. Prevalence and morbidity of primary immunodeficiency diseases, United States 2001-2007. J Clin Immunol. (2014) 34:954–61. doi: 10.1007/s10875-014-0102-8
2. Filipovich AH, Mathur A, Kamat D, Shapiro RS. Primary immunodeficiencies: genetic risk factors for lymphoma. Cancer Res. (1992) 52(19 Suppl):5465s–7s.
3. Vajdic CM, Mao L, van Leeuwen MT, Kirkpatrick P, Grulich AE, Rimington S. Are antibody deficiency disorders associated with a narrower range of cancers than other forms of immunodeficiency? Blood. (2010) 116:1228–34. doi: 10.1182/blood-2010-03-272351
4. Fedorova A, Sharapova S, Mikhailevskaya T, Aleshkevich S, Proleskovskaia I, Stsegantseva M, et al. Non-Hodgkin lymphoma in children with primary immunodeficiencies: clinical manifestations, diagnosis, and management, belarusian experience. Lymphoma. (2015) 2015:10. doi: 10.1155/2015/123548
5. Taskinen M, Jeskanen L, Karjalainen-Lindsberg ML, Makitte A, Makitte O, Ranki A. Combating cancer predisposition in association with idiopathic immune deficiency: a recurrent nodal and cutaneous T-cell lymphoproliferative disease in a patient with cartilage-hair hypoplasia. Clin Lymph Myeloma Leuk. (2013) 13:73–6. doi: 10.1016/j.clml.2012.06.005
6. Niжland ML, Koens L, Pals ST, Berge I, Bemelman FJ, Kersten MJ. Clinicopathological characteristics of T-cell non-Hodgkin lymphoma arising in patients with immunodeficiencies: a single-center case series of 25 patients and a review of the literature. Haematologica. (2018) 103:486–96. doi: 10.3324/haematol.2017.160997
7. Schmidt RE, Grimbacher B, Witte T. Autoimmunity and primary immunodeficiency: two sides of the same coin? Nat Rev Rheumatol. (2017) 14:7–18. doi: 10.1038/nrrheum.2017.198
8. Mortaz E, Tabarsi P, Mansouri D, Khosravi A, Garsen I, Velayati A, et al. Cancers related to immunodeficiencies: update and perspectives. Front Immunol. (2016) 7:365. doi: 10.3389/fimmu.2016.00365
9. Shapiro RS, Robbins N, Cowen LE. Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol Mol Biol Rev. (2011) 75:213–67. doi: 10.1128/MMBR.00045-10
10. Picard C, Bobby Gaspar H, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, et al. International union of immunological societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity. J Clin Immunol. (2018) 38:96–128. doi: 10.1007/s10875-017-0464-9
11. Salavoura K, Kolialexi A, Tzangaris G, Mavrou A. Development of cancer in patients with primary immunodeficiencies. Anticancer Res. (2008) 28:1263–9. Retrieved from: http://ar.iiarjournals.org/content/28/2B/1263.long
12. Mayor PC, Eng KH, Singel KL, Abrams SI, Odunsi K, Moysich KB, et al. Cancer in primary immunodeficiency diseases: cancer incidence in the United States immune deficiency network registry. J Allergy Clin Immunol. (2018) 141:1028–35. doi: 10.1016/j.jaci.2017.05.024

13. Moshou D, Martin E, Carpenter W, Lim A, Callebaut I, Canioni D, et al. Whole-exome sequencing identifies Coronin-1A deficiency in 3 siblings with immunodeficiency and EBV-associated B-cell lymphoproliferation. J Allergy Clin Immunol. (2013) 131:1594–603. doi: 10.1016/j.jaci.2013.01.042

14. Toita N, Hatano N, Ono S, Yamada M, Kobayashi R, Kobayashi I, et al. Epstein-Barr virus-associated B-cell lymphoma in a patient with DNA ligase IV (LIG4) syndrome. Am J Med Genet A. (2007) 143A:742–5. doi: 10.1002/ajmg.a.31644

15. Moshous D, Panneetier C, Chasseval RD, Reit FL, Cavazzana-Calvo M, Romana S, et al. Partial T and B lymphocyte immunodeficiency and predisposition to lymphoma in patients with hypomorphic mutations in Artemis. J Clin Invest. (2005) 113:381–7. doi: 10.1172/JCI16774

16. Schuetz C, Huck K, Gudowius P, Megahed M, Feyen O, Hubner B, et al. An immunodeficiency disease with RAG mutations and granulomas. New Engl J Med. (2008) 358:2030–8. doi:10.1056/NEJMoa073966

17. Enders A, Fisch P, Schwarz K, Duffner U, Pannicke U, Nikolopoulos E, et al. A severe form of human combined immunodeficiency due to mutations in DNA ligase IV. J Immunol. (2006) 176:3060–8.

18. Newell A, Dadi H, Goldberg R, Nakan Y, Grunebaum E, Roifman CM. Diffuse large B-cell lymphoma as presenting feature of Zap-70 deficiency. J Allergy Clin Immunol. (2011) 127:517–20. doi: 10.1016/j.jaci.2010.09.016

19. Kapoor N, Jung K, Engelhard D, Filler J, Shalit I, Landreth KS, et al. Epstein-Barr virus-associated Hodgkin's disease in a patient with Wiskott-Aldrich syndrome. J Pediatr Hematol. (2001) 23:195–7. doi: 10.1097/00167255-200104000-00006

20. Kreipe HH, et al. First occurrence of plasmablastic lymphoma in adenosine deaminase deficient severe combined immunodeficiency patient and review of the literature. Front Immunol. (2013) 4:113. doi: 10.3389/fimmu.2013.00113

21. Kaufman DA, Moissidis IJ, Bocchini JA Jr, Hershfield MS, Bahn A, et al. Artemis. J Immunol. (2003) 169:381–7. doi: 10.4049/jimmunol.169.1.381

22. Husain M, Grunebaum E, Naqvi A, Atkinson A, Ngan BY, Aiuti A, et al. Distinct clonotypic Epstein-Barr virus-induced fatal lymphoproliferative disorder in a patient with Wiskott-Aldrich syndrome. Cancer. (1993) 72:1376–81. doi: 10.1002/1097-0424(19930815)72:4<1376::AID-CNCR2820720437>3.0.CO;2-Q

23. Genel F, Ozbek E, Ozek G, Vergin C, Ortac R, Santisteban I, et al. Adenosine deaminase deficiency, following unsustained engraftment of hematopoietic cells. J Pediatr. (1989) 115:805–8.

24. Taskinen M, Ranki A, Pukkala E, Jeskanen L, Kaitila I, Makite O. Extended follow-up of the Finnish cartilage-hair hypoplasia cohort confirms high incidence of non-Hodgkin lymphoma and basal cell carcinoma. Am J Med Genet Part A. (2008) 146a:2370–5. doi: 10.1002/ajmg.a.32478

25. Palenzuela G, Bernard F, Gardiner Q, Mondain M. Malignant B cell non-Hodgkin's lymphoma of the larynx in children with Wiskott-Aldrich syndrome. Int J Pediatr Otorhinolaryngol. (2003) 67:989–93. doi: 10.1016/S0165-5876(03)00153-1

26. Bennett JA, Bayerl MG. Epstein-barr virus-associated extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT Lymphoma) arising in the parotid gland of a child with ataxia telangiectasia. J Pediatr Hematol Oncol. (2015) 37:e114–7. doi: 10.1097/MPH.0b013e318293d496

27. Meister MT, Voss S, Schwabe D. Treatment of EBV-associated nodular sclerosing Hodgkin lymphoma in a patient with ataxia telangiectasia with brentuximab vedotin and reduced COPP plus rituximab. Pediatr Blood Cancer. (2015) 62:2018–20. doi: 10.1002/pbc.25621

28. Seier R, Sykora KW, Woessmann W, Maeker-Kolhoff R, Sauer M, Kreipe HH, et al. Allogeneic-matched sibling stem cell transplantation in a 13-year-old boy with ataxia telangiectasia and EBV-positive non-Hodgkin lymphoma. Bone Marrow Transplant. (2016) 51:1271–4. doi: 10.1038/bmt.2016.93

29. Du S, Scuderi R, Malicki DM, Willert J, Bastian J, Weidner N. Hodgkin's and non-Hodgkin's lymphomas occurring in two brothers with Wiskott-Aldrich syndrome and review of the literature. Pediatr Devel Pathol. (2011) 14:64–70. doi: 10.2350/10-01-0787-CR1

30. Pasic S, Vujic D, Djuricic S, Jevtic D, Grujic B. Burkitt lymphoma-induced ileoileal intussusception in a Wiskott-Aldrich syndrome. J Pediatr Hematol. (2006) 28:48–9. 

31. Nakanishi M, Kikuta H, Tomizawa K, Kojima K, Ishizaka A, Okano M, et al. Distinct clonotypic Epstein-Barr virus-induced fatal lymphoproliferative disorder in a patient with Wiskott-Aldrich syndrome. Cancer. (1993) 72:1376–81. doi: 10.1002/1097-0424(19930815)72:4<1376:AID-CNCR2820720437>3.0.CO;2-Q

32. Gulley ML, Chen CL, Raab-Traub N. Epstein-Barr virus-related lymphomagenesis in a child with Wiskott-Aldrich syndrome. Hematol Oncol. (1993) 11:139–45. doi: 10.1002/hon.2900110304

33. Nakanishi M, Kikuta H, Tomizawa K, Kojima K, Ishizaka A, Okano M, et al. Distinct clonotypic Epstein-Barr virus-induced fatal lymphoproliferative disorder in a patient with Wiskott-Aldrich syndrome. Cancer. (1993) 72:1376–81. doi: 10.1002/1097-0424(19930815)72:4<1376:AID-CNCR2820720437>3.0.CO;2-Q

34. Gregorowicz H, Chrzanoszewska KH, Dzierzanowska-Fangrat K, Waliukinska A, Pietrucha B, Zapasnik A, et al. Nijmegen breakage syndrome: Long-term monitoring of viral and immunological biomarkers in peripheral blood before development of malignancy. Clin Immunol. (2010) 135:440–7. doi: 10.1016/j.clim.2010.01.008
45. Wolska-Kusznier B, Gregorek H, Chrzanowska K, Piatosa B, Pietrucha B, Heropolitanska-Pliszka E, et al. Nijmegen breakage syndrome: clinical and immunological features, long-term outcome and treatment options - a retrospective analysis. J Clin Immunol. (2015) 35:538–49. doi: 10.1007/s10875-015-0186-9

46. Baykal C, Kavak A, Gulcan P, Buyukbakhshi N. Dyskeratosis congenita associated with three malignancies. J Eur Acad Dermatol Venereol. (2003) 17:216–8. doi: 10.1046/j.1468-3083.2003.00585.x

47. Basiratnia M, Baradaran-Heravi A, Yavarian M, Geramizadeh B, Karimi M. Non-hodgkin lymphoma in a child with schimke immuno-osseous dysplasia. Iran J Med Sci. (2011) 36:222–5. Retrieved from: http://ijms.sums.ac.ir/index.php/IJMS/article/view/771/200

48. Baradaran-Heravi A, Raams A, Lubieniecka J, Cho KS, DeHaai KA, Taha D, Boerkoel CF, Balfe JW, Khalifah M, Sloan EA, Barbar M, et al. Fatal lymphoproliferative disorder in a child with Schimke immuno-osseous dysplasia. Am J Med Genet Part A. (2012) 158a:2240–13. doi: 10.1002/ajmg.a.35532

49. Taha D, Boerkoel CF, Balfe JW, Khalifah M, Slosan EA, Barbar M, et al. Fatal lymphoproliferative disorder in a child with Schimke immuno-osseous dysplasia. Am J Med Genet Part A. (2004) 131:194–9. doi: 10.1002/ajmg.a.30356

50. Fuentes-Pérez G, Saornil MA, Herreras JM, Alonso-Ballesteros M, Sánchez PS, García-Tejeiro M. CHARGE association, hyper-immunoglobulin M syndrome, and conjunctival MALT lymphoma. Cornea. (2007) 26:864–7. doi: 10.1097/ICO.0b013e3180c77d6e

51. Kracker S, Curtis J, Ibrahim MA, Sediva A, Salisbury J, Campr V, et al. Occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase delta syndrome. J Allergy Clin Immunol. (2014) 134:233–6. doi: 10.1016/j.jaci.2014.02.020

52. Coultier T, Chandra A, Bacon CM, Babar J, Curtis J, Scrooten N, et al. Clinical spectrum and features of activated phosphoinositide 3-kinase delta syndrome: a large patient cohort study. J Allergy Clin Immunol. (2017) 139:597–606.e4. doi: 10.1016/j.jaci.2016.06.021

53. Angulo I, Vadas O, Garcon F, Banham-Hall E, Plagnol V, Leahy TR, et al. Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage. Science. (2013) 342:866–71. doi: 10.1126/science.1243292

54. Mellemkjaer I, Hammarstrom L, Andersen V, Yuen J, Hellmann C, Barington T, et al. Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study. Clin Exp Immunol. (2002) 129:345–50. doi: 10.1046/j.1365-2249.2002.02004.x

55. Gelmann E, Anderson T, Jaffe E, Broder S. Chemotherapy for lymphoma in a patient with common variable immunodeficiency: case report, literature review, and recommendations for chemotherapy in immunodeficient patients. Arch Int Med. (1992) 142:90–2. doi: 10.1001/archinte.1992.00400140029017

56. Aghamohammadi A, Parvaneh N, Tirgari F, Mahjoob F, Movahedi M, et al. Malignant lymphoma of jejunum with common variable hypogammaglobulinemia and diffuse nodular hyperplasia of the small intestine. A case study and literature review. J Clin Gastroenterol. (1992) 15:128–35. doi: 10.1097/00004836-199209000-00010

57. Quinti I, Sorensa A, Spadaro G, Martino S, Donnanno S, Agostini C, et al. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immunol. (2007) 27:308–16. doi: 10.1007/s10875-007-9075-1

58. Hermaszewski RA, Webster AD. Primary hypogammaglobulinemia: a survey of clinical manifestations and complications. Quart J Med. (1993) 86:31–42.

59. Reichenberger F, Wyser C, Gonon M, Cathomas G, Tamh M. Pulmonary mucosa-associated lymphoid tissue lymphoma in a patient with common variable immunodeficiency syndrome. Respir. (2001) 68:109–12. doi: 10.1159/000050475

60. Chapel H, Lucas M, Lee M, Bjorkander J, Webster D, Grimbacher B, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. (2008) 112:277–86. doi: 10.1182/blood-2007-11-124545

61. Resnick ES, Mosher EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. (2012) 119:1650–7. doi: 10.1182/blood-2011-09-377945

62. Wobser M, Kerstan A, Kneitz H, Goebeler M, Kunzmann V, Rosenwald A, et al. Primary cutaneous marginal zone lymphoma with sequential development of nodal marginal zone lymphoma in a patient with selective immunoglobulin A deficiency. J Cutaneous Pathol. (2013) 40:1035–41. doi: 10.1111/j.1365-2223.2012.01177.x

63. Pace R, Vinh DC. Autoimmune lymphoproliferative syndrome and Epstein-Barr virus-associated lymphoma: an adjunctive diagnostic role for monitoring EBV viremia? Case Rep Immunol. (2013) 2013:245893. doi: 10.1155/2013/245893

64. Sharapova SO, Fedorova AS, Pashchenko OE, Vahliarskaya SS, Logunova NF, et al. Simultaneous manifestation of fulminant infectious mononucleosis with haemophagocytic syndrome and B-cell lymphoma in a patient with primary adult-onset hypogammaglobulinemia and nodular lymphoid hyperplasia of the small intestine. Vitam Horm. (2015) 92:34–48. doi: 10.1016/9781455972353.00017-8

65. Eghel RM, de Kraker J, Slater R, Purtilo DT. Documentation of Burkitt lymphoma with [t(8;14)(q24;q32)] in X-linked lymphoproliferative disease.
80. Alme C, Satwani P, Aloebid B, Bhagat G, Kelly KM. Atypical clinical course in pediatric hodgkin lymphoma: association with germline mutations in interleukin-2-inducible T-cell kinase. J Pediatr Hematol Oncol. (2015) 37:507–8. doi: 10.1097/MPH.0000000000000366

81. Cipe FE, Aydogmus C, Serwas NK, Tugcu D, Demirkaya M, Biçici FA, et al. ITK deficiency: how can EBV be treated before lymphoma? Pediatr Blood Cancer. (2015) 62:2247–8. doi: 10.1002/pbc.25648

82. Shamriz O, Vilk SR, Wolf DG, Ta-Shma A, Averbuch D, Weintraub M, et al. Hematopoietic stem cell transplantation conditioning with use of rituximab in EBV related lymphoproliferative disorders. Clin Immunol. (2014) 151:79–83. doi: 10.1016/j.clim.2014.01.007

83. Linka RM, Risse SL, Bienemann K, Werner M, Linka Y, Krux F, et al. Loss-of-function mutations within the IL-2-inducible kinase ITK in patients with EBV-associated lymphoproliferative diseases. Leukemia. (2012) 26:963–71. doi: 10.1038/leu.2011.371

84. Stepensky P, Weintraub M, Yanir A, Revel-Vilk S, Huck K, et al. IL-2-inducible T-cell kinase deficiency: clinical presentation and therapeutic approach. Haematologica. (2011) 96:472–6. doi: 10.3324/haematol.2010.039390

85. Huk K, Feyen O, Niehues T, Ruschendorf F, Hubner N, Laws HJ, et al. Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. J Clin Invest. (2009) 119:1350–8. doi: 10.1172/JCI37901

86. Izawa K, Martin E, Soudais C, Bruneau J, Boutboul D, Rodriguez R, et al. Inherited CD70 deficiency in humans reveals a critical role for the CD70-CD27 pathway in immunity to Epstein-Barr virus infection. J Exp Med. (2017) 214:73–89. doi: 10.1084/jem.20160784

87. Abbodhassani H, Edwards ES, Ikinciogullari A, Jing H, Borte S, Buggert M, et al. Combined immunodeficiency and Epstein-Barr virus-induced B cell malignancy in humans with inherited CD70 deficiency. J Exp Med. (2017) 214:91–106. doi: 10.1084/jem.20160849

88. Allkhairy OK, Perez-Becker R, Driessen GJ, Abolhassani H, van Montfrans J, Borte S, et al. Novel mutations in TNFRSF7/CD27: Clinical, immunologic, and genetic characterization of human CD70 deficiency. J Allergy Clin Immunol. (2015) 136:703–12.e10. doi: 10.1016/j.jaci.2015.02.022

89. Li FY, Chaigne-Delalande B, Su H, Uzel G, Matthews H, Lenardo MJ. Hypogammaglobulinemia, infections, and myelokathexis. Ann Hematol. (2002) 81:470–3. doi: 10.1007/s00277-002-0489-9

90. Gammon B, Robson A, Deonizio J, Arkin L, Guitart J. CD8(+) granulomatous cutaneous T-cell lymphoma: a potential association with immunodeficiency. J Am Acad Dermatol. (2014) 71:555–60. doi: 10.1016/j.jaad.2014.03.028

91. Pasic S, Vujic D, Fiorini M, Notarangelo LD. T-cell lymphoblastic leukemia/lymphoma in Niemegk breakage syndrome. Haematologica. (2004) 89:E127. Retrieved from: http://www.haematologica.org/content/89/8/ECR27

92. Alkhairy OK, Perez-Becker R, Driessen GJ, Abolhassani H, van Montfrans J, Borte S, et al. Combined immunodeficiency and Epstein-Barr virus-induced B cell malignancy in humans with inherited CD70 deficiency. J Exp Med. (2017) 214:91–106. doi: 10.1084/jem.20160849

93. El Khairy OK, Perez-Becker R, Driessen GJ, Abolhassani H, van Montfrans J, Borte S, et al. Inherited CD70 deficiency in humans reveals a critical role for the CD70-CD27 pathway in immunity to Epstein-Barr virus infection. J Exp Med. (2017) 214:73–89. doi: 10.1084/jem.20160784

94. Abdollahi T, Edwards ES, Ikinciogullari A, Jing H, Borte S, Buggert M, et al. Combined immunodeficiency and Epstein-Barr virus-induced B cell malignancy in humans with inherited CD70 deficiency. J Exp Med. (2017) 214:91–106. doi: 10.1084/jem.20160849

95. Alkhairy OK, Perez-Becker R, Driessen GJ, Abolhassani H, van Montfrans J, Borte S, et al. Novel mutations in TNFRSF7/CD27: Clinical, immunologic, and genetic characterization of human CD70 deficiency. J Allergy Clin Immunol. (2015) 136:703–12.e10. doi: 10.1016/j.jaci.2015.02.022

96. Li FY, Chaigne-Delalande B, Su H, Uzel G, Matthews H, Lenardo MJ. XMFN disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus. Blood. (2014) 123:2148–52. doi: 10.1182/blood-2013-11-538686

97. Di Cooperative Study: a novel mutation in the ITH+ECR27 variable hypogammaglobulinemia complicated by an unusual T-cell-receptor deficiency and history of infantile inflammatory bowel disease. J Pediatr Gastroenterol Nutr. (2016) 63:e15–7. doi: 10.1097/MPG.0000000000001532

98. OR M. No immunosurveillance in human IL-10R deficiency. Blood. (2013) 122:3702–3. doi: 10.1182/blood-2013-10-531657

99. Hauck F, Voss R, Urban C, Seidel MG. Intrinsic and extrinsic causes of malignancies in patients with primary immunodeficiency disorders. J Aller Clin Immunol. (2018) 141:39–68.e4. doi: 10.1016/j.jaci.2017.06.009

100. de Miranda NF, Bjorkman A, Pan-Hammarstrom Q. DNA repair: the link between primary immunodeficiency and cancer. Ann NY Acad Sci. (2012) 1246:50–63. doi: 10.1111/j.1749-6632.2011.06322.x

101. Keijzers G, Bakula D, Schreiby-Knudsen M. Monogenic diseases of DNA repair. N Engl J Med. (2017) 377:1868–76. doi: 10.1056/NEJMra1703366

102. Rezaei N, Hedayat M, Aghamohammadi A, Nichols KE. Primary immunodeficiency diseases associated with increased susceptibility to viral
Riaz et al. Lymphomas in PID infections and malignancies. J Allergy Clin Immunol. (2011) 127:1329–41.e2; quiz 42–3. doi: 10.1016/j.jaci.2011.02.047

116. Shabani M, Nichols KE, Rezaei N. Primary immunodeficiencies associated with EBV-Induced lymphoproliferative disorders. Crit Rev Oncol Hematol. (2016) 108:109–27. doi: 10.1016/j.critrevonc.2016.10.014

117. Latour S, Winter S. Inherited immunodeficiencies with high predisposition to Epstein-Barr virus-driven lymphoproliferative diseases. Front Immunol. (2018) 9:1103. doi: 10.3389/fimmu.2018.01103

118. Zuniga EI, Harker JA. T-cell exhaustion due to persistent antigen: quantity not quality? Eur J Immunol. (2012) 42:2285–9. doi: 10.1002/eji.201242852

119. Disis ML. Mechanism of action of immunotherapy. Semin Oncol. (2014) 41(Suppl. 5):S3–13. doi: 10.1053/j.seminoncol.2014.09.004

120. Johnson DB, Chandra S, Sosman JA. Immune checkpoint inhibitor toxicity in 2018. JAMA. (2018) 320:1702–3. doi: 10.1001/jama.2018.13995

121. Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. (2013) 19:3462–73. doi: 10.1158/1078-0432.CCR-13-0855

122. Yoon H, Park S, Ju H, Ha SY, Sohn I, Jo J, et al. Integrated copy number and gene expression profiling analysis of Epstein-Barr virus-positive diffuse large B-cell lymphoma. Genes Chromosomes Cancer. (2015) 54:383–96. doi: 10.1002/gcc.22249

123. Al-Humood S, AlQallaf A, Al-Shemmari S, Al-Faris L, Al-Ayadhy B. Genetic and immunohistochemical characterization of Epstein-Barr virus-associated diffuse large B-cell lymphoma. Acta Haematol. (2014) 131:1–10. doi: 10.1159/000350493

124. Ulldrick TS, Little RF. How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus. Blood. (2015) 125:1226–35; quiz 355. doi: 10.1182/blood-2014-08-551598

125. Gennery AR, Slatter MA, Grandin L, Taupin P, Cant AJ, Veys P, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol. (2010) 126:602–10.e1–11. doi: 10.1016/j.jaci.2010.06.015

126. Wehr C, Gennery AR, Lindemans C, Schulz A, Hoenig M, Marks R, et al. Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency. J Allergy Clin Immunol. (2015) 135:988–97.e6. doi: 10.1016/j.jaci.2014.11.029

127. Pai S-Y, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC, et al. Transplantation outcomes for severe combined immunodeficiency, 2000–2009. N Engl J Med. (2014) 371:434–46. doi: 10.1056/NEJMoa1401777

128. Ngwube A, Hanson IC, Orange J, Rider NL, Seeborg F, Shearer W, et al. Outcomes after allogeneic transplant in patients with Wiskott-Aldrich syndrome. Biol Blood Marrow Transplant. (2018) 24:537–41. doi: 10.1016/j.bbmt.2017.11.019

129. Fox TA, Chakraverty R, Burns S, Carpenter B, Thomson K, Lowe D, et al. Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency. Blood. (2018) 131:917–31. doi: 10.1182/blood-2017-09-807487

130. Verhoeven D, Stoppelenburg AJ, Meyer-Wentrup F, Boes M. Increased risk of hematologic malignancies in primary immunodeficiency disorders: opportunities for immunotherapy. Clin Immunol. (2018) 190:22–31. doi: 10.1016/j.clim.2018.02.007

131. Bomken S, van der Werff Ten Bosch J, Attarbaschi A, Bacon CM, Borkhardt A, Boztug K, et al. Current understanding and future research priorities in malignancy associated with inborn errors of immunity and DNA repair disorders: the perspective of an interdisciplinary working group. Front Immunol. (2018) 9:2912. doi: 10.3389/fimmu.2018.02912

132. Naikunam Y, Gratzingier D, Chadburn A, Goodlad JR, Chan JKC, Said J, et al. Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal. Blood. (2018) 132:1871–8. doi: 10.1182/blood-2018-04-842559

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Riaz, Faridi, Patnaik and Abraham. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). No use, distribution or reproduction is permitted which does not comply with these terms.